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Tissue transglutaminase (tTG) is a GTPase and acyl transferase which catalyzes the 
formation of covalent crosslinks between two protein substrates. tTG expression and activation 
are frequently up-regulated in different types of human cancer, where it has been shown to be 
important for enhancing cell motility. Using HeLa cervical carcinoma cells as a model system, I 
show that a membrane-associated pool of tTG becomes activated and re-distributes to the leading 
edges of migrating cells upon EGF stimulation. Immunoprecipitations of tTG from the 
membrane fractions of EGF-treated HeLa cells led to the discovery that tTG binds the heat shock 
protein (Hsp)70 family of molecular chaperones. tTG and Hsp70 co-localize at leading edges, 
and this localization is dependent on the ATP hydrolytic activity of Hsp70, as inhibitors against 
this function prevent both tTG and Hsp70 from localizing to leading edges. More importantly, 
these inhibitors also block the EGF-dependent migration of HeLa cells and the constitutive 
migration of MDA-MB231 cells, suggesting that Hsp70 helps localize tTG to leading edges to 
facilitate its role in promoting cell migration. 
 While tTG has been shown to influence a number of aspects of cancer progression, to 
what degree tTG works with oncogenic proteins to elicit these outcomes versus its intrinsic 
ability to impact malignant transformation is unknown. Thus, I have examined how ectopic 
expression of tTG in a normal (non-transformed) cellular context influences the behavior of 
these cells. Using NIH3T3 fibroblasts stably expressing the vector alone or a Myc-tagged form 
of wild-type tTG, I found that tTG strongly protected these cells from serum-starvation-induced 
apoptosis by activating the PI3-kinase/mTOR/p70 S6-kinase pathway.  tTG binds c-Src and PI3-
kinase, and the formation of this complex is critical for the activation of the PI3-kinase signaling 
pathway. Activation of PI3-kinase signaling is essential for tTG’s ability to promote cell 
survival, as inhibition of any component in this pathway, including Src, PI3-kinase, or mTOR, 
eliminates the protective effect afforded to the cells by tTG expression. 
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meet increasing proliferative demands with the goal of designing therapies to target these tumor 
cells based on their metabolic signatures.  
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CHAPTER 1 
 
Overview 
 
 Tissue transglutaminase (tTG) is a dual-function protein which couples an ability to bind 
and hydrolyze guanine triphosphate (GTP) with an enzymatic transamidation activity that allows 
it to generate covalent crosslinks between two protein substrates or between a protein and a 
polyamine (1-3).  Tissue transglutaminase, which is also referred to as transglutaminase 2 
(TGase-2 or TG2), is an 87 kilodalton protein encoded by the TGM2 gene located on human 
chromosome 20q11-12 (4).  It is one of nine proteins belonging to the transglutaminase family 
whose other members include Factor XIII, Band 4.2, and TG1, TG3, TG4, TG5, TG6, and TG7.  
Each of these family members, with the exception of Band 4.2, exhibits enzymatic 
transamidation activity, but only tTG, TG3, and TG5 are known to bind GTP (2,5).  Table 1.1 
summarizes what is known about the tissue distribution, localization, biochemical activity and 
function of each of the various transglutaminase family members.  
 To date, most of the research carried out on the transglutaminases has been focused on 
Factor XIII, and TG1-3, while the remaining family members have not yet been fully 
characterized.  Factor XIII circulates in plasma and is involved in fibrin stabilization and blood 
clotting (6).  TG1 and TG3 are expressed primarily in keratinocytes and participate in the 
terminal differentiation of these cells (4).  In contrast, the ubiquitous expression of tTG (TG2) 
has prompted studies of its function in many different cellular contexts.  The results of these 
studies have shown that tTG participates in various physiological processes including 
differentiation, maintenance of the extracellular matrix, wound healing, cell migration, and 
1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Transglutaminase family members. Tissue transglutaminase (tTG or TG2) 
belongs to the transglutaminase family, whose other members include TG1, TG3-7, Factor 
XIII, and Band 4.2. The table highlights the tissue distribution, cellular localization, 
biochemical activities, and function of each family member. Note that some members are 
ubiquitously expressed, while others show specific tissue distributions. This table was adapted 
from that generated by Facchiano et al. (5). 
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3
apoptosis (7-15).  In addition, tTG expression and/or activation is often up-regulated in various 
human disease states including celiac disease, neurodegenerative disorders (Alzheimer’s, 
Parkinson’s, and Huntington’s diseases), and cancer (16-22).  A number of questions remain 
regarding how tTG is able to impact so many cellular processes and by extension, many disease 
states.  What we have learned so far about the structure, function, and regulation of tTG has 
deepened our understanding of this protein and its importance to human disease.  Moreover, it 
has given us reason to believe that this protein may be a worthy target for the development of 
therapies to combat these diseases.  
Structure & Function 
Our lab first became interested in tTG after it was identified in a proteomic screen 
looking for novel GTP-binding proteins (G-proteins) associated with the nucleus (23).  While our 
interest in tTG was just beginning, other groups had been investigating tTG for some time and 
had classified it as a member of a new family of GTP binding proteins (called Gh) by showing 
that in rat liver tTG can bind and hydrolyze GTP and transduce signals from the α1B/D-
adrenergic receptor to its downstream effector, phospholipase Cδ1 (3).  A schematic of this 
activity is depicted in Figure 1.1, top panel.  Interestingly, however, sequence analysis conducted 
on tTG revealed that it lacked the conventional guanine nucleotide-binding motif that is found in 
both families of large and small G-proteins, suggesting that tTG binds GTP via a unique 
mechanism.  This idea was confirmed in 2002 when the first crystal structure of tTG bound to 
GDP was solved by our laboratory and it was discovered that tTG possesses a novel guanine 
nucleotide-interacting motif (24).  While large G-proteins have a helical domain in the α subunit 
which promotes high affinity binding of guanine nucleotides, and small G-proteins instead use 
Mg
2+
 to facilitate nucleotide binding, the structure of tTG shows neither of these features 
4
 Figure 1.1 Enzymatic functions of tissue transglutaminase. tTG functions as both a 
GTPase and an acyl transferase which catalyzes the formation of protein crosslinks. The 
ability of tTG to bind and hydrolyze GTP serves to mediate signals from the α1B/D-
adrenergic receptor to its downstream effector, phospholipase Cδ1 (PLCδ1), which results in 
phosphoinositide hydrolysis (top panel). In contrast, tTG’s calcium-dependent transamidation 
activity leads to the generation of covalent crosslinks between a glutamine-containing protein 
substrate and a primary amino group found either in a lysine-containing protein substrate or in 
a polyamine (bottom panel). 
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6
(25,26).  Instead, a series of positively-charged residues surround the nucleotide-binding region, 
the most important of which is Arg580, because it forms hydrogen bonds with the guanine ring 
and the α- and β-phosphates of GDP.  
In contrast to the extensively studied GTPase function of the more conventional large and 
small families of G-proteins, very little is known about the regulation of tTG’s GTPase activity 
and how this function contributes to tTG’s role in cellular processes.  Researchers have yet to 
determine whether there is a specific guanine nucleotide exchange factor (GEF) or GTPase 
activating protein (GAP) for tTG or whether such regulation is even needed for tTG to bind and 
hydrolyze GTP. 
Instead, most of the research conducted on tTG to date has focused on its function as an 
acyl transferase.  In a calcium-dependent transamidation reaction, tTG catalyzes the formation of 
amide bonds (crosslinks) between the carboximide group of a protein-bound glutamine and a 
primary amino group, which can be found in the ε-amino group of a protein-bound lysine residue 
or in a polyamine (Figure 1.1, bottom panel) (1,2).  Studies have revealed that tTG, as well as 
nearly all of its closely related family members (see Table 1.1), shares a catalytic triad motif with 
members of the cysteine protease family, consisting of residues Cys277, His335, and Asp358.  
The reaction takes place in two steps, with the first being the transient acylation of Cys277 when 
it performs a nucleophilic attack on the glutamine-containing substrate and generates an acyl-
thiolate intermediate.  The second step involves the primary amino group of the second substrate 
executing a nucleophilic attack resulting in the deacylation of Cys277 and the release of the 
crosslinked products and one molecule of ammonia.  Mutation of Cys277 results in a form of 
tTG that is unable to carry-out this crosslinking reaction, thus confirming that this residue is 
critical for the transamidation activity (27,28).  Interestingly, Band 4.2, the only transglutaminase 
7
family member without crosslinking activity (see Table 1.1) has an alanine instead of a cysteine 
at position 277, further demonstrating the importance of this residue in catalyzing the 
transamidation reaction.  Likewise, mutation of His335 or Asp358, the other residues that make 
up the catalytic triad, also makes tTG transamidation-defective (1). The crystal structure of tTG 
solved in 2007 showing it bound to an inhibitor Ac-P(DON)LPF-NH2 (where DON is the 
electrophilic amino acid 6-diazo-5-oxo-L-norleucine) which mimics a natural PQLPY motif 
found in gluten peptides, further supports this mechanism and the involvement of this catalytic 
triad (29).  Much of the work performed on tTG up to this point has been focused on this activity 
of tTG, in part because of access to crosslinking inhibitors, such as monodansylcadaverine 
(MDC) and 1,3,4,5-tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride (T101).  
In addition to confirming mechanistic details regarding tTG’s biochemical activities, the 
crystal structures of tTG revealed that it can adopt two drastically different conformations; an 
open conformation and a closed conformation (Figure 1.2).  tTG possesses four structural 
domains: an N-terminal β-sandwich domain, the catalytic core which harbors the nucleotide 
binding site and the transamidation active site, followed by two C-terminal β-barrel domains 
(30).  In Figure 1.2, the structure on the left, which was solved by our laboratory, shows tTG 
bound to GDP (24).  The two C-terminal β-barrels are folded over the catalytic core, thus 
preventing transamidation substrates from accessing the active site.  For this reason, this 
conformation has been termed the “closed” conformation of tTG.  In contrast, the crystal 
structure of tTG on the right, solved by Pinkas et al., shows it bound to an inhibitor which 
mimics its gluten peptide substrate, and it adopts an essentially linear conformation where the 
two C-terminal β-barrels of tTG have swung away from the catalytic core to provide complete 
8
 Figure 1.2 Crystal structures of tTG.  Two crystal structures of tTG have been solved and 
have shown that tTG can adopt drastically different conformations. The structure on the left 
depicts the “closed” conformation of tTG which occurs when tTG is bound to GTP or GDP 
(in this case, GDP). In this structure, the C-terminal β-barrels fold over the catalytic core and 
block access to the transamidation active site. The structure on the right, represents the “open” 
conformation of tTG, with tTG bound to a peptide-substrate mimic. When tTG reaches a 
nucleotide-free state, the C-terminal β-barrels swing away from the catalytic core and provide 
substrates with access to the transamidation active site. 
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access of substrates to the active site (where the inhibitor/substrate was shown to bind) (29).  
Therefore, this conformation of tTG has been called the “open” conformation.   
Solving the open and closed structures of tTG helped solidify the hypothesis that the 
GTP-binding and enzymatic transamidation activities of tTG reciprocally regulate one another, 
such that when tTG is bound to nucleotide, its transamidation function is inactive.  However, 
when tTG achieves a nucleotide-free state, and is able to bind calcium, it can function as an acyl 
transferase.  This was supported by studies using rat tTG, whereby it was shown that the binding 
of guanine nucleotides (either GTP or GDP) to tTG inhibited its transamidation activity (3).  
Additionally, research analyzing the binding of GDP or GTPγS (a non-hydrolyzable form of 
GTP) to recombinant human tTG revealed a dose-dependent inhibition of tTG’s transamidation 
activity (31).  This reciprocal regulation of tTG’s enzymatic functions, as well as the detailed 
information provided by solving the crystal structures that show the open and closed 
conformations of tTG, presented our laboratory and others with a unique opportunity, namely, to 
mutate specific residues that are important for tTG to carry-out a specific biochemical activity 
(i.e. to bind GTP or GDP or crosslink) and determine how these changes would impact cellular 
behavior. 
With this idea in mind, our laboratory mutated wild-type tTG, which has a Kd of 400 nM 
for binding to GTP, to generate a form of tTG that was no longer capable of binding guanine 
nucleotides.  Specifically,  Arg580, a residue which makes critical contacts with GDP, was 
changed to a lysine (tTG R580K) (32).  Although incapable of binding nucleotide, this mutant 
retained its transamidation activity.  Surprisingly, when ectopically expressed in a variety of cell 
types, this mutant induced cell death, unlike wild-type tTG which cells tolerate well.  With the 
idea that this apoptotic response was due to the fact that the tTG R580K mutant exhibited high, 
11
un-regulated transamidation activity, a double mutant was made where both Arg580 and Cys277 
were changed. Cys277 is the critical cysteine residue in the transamidation active site (the 
catalytic triad), that when mutated, completely eliminates transamidation activity (27).  
However, comparing the effects of ectopically expressing the single mutant (tTG R580K) or the 
double mutant (tTG R580K/C277A) in cells revealed that both mutant forms of tTG induced a 
comparable amount of cell death (32).  Thus, the apoptotic response induced by ectopically 
expressing the nucleotide-binding defective form of tTG in cells is not the result of aberrant 
crosslinking activity.  These findings have led us to propose a new hypothesis as to why the 
mutant form of tTG (tTG R580K) induces cell death.  Given that this mutant cannot bind 
nucleotide, we believe that it adopts a more open conformation and that this structure is harmful 
to cells.  When tTG opens up, it might bind to a protein(s) necessary for cell viability, perhaps 
inactivating it or preventing it from localizing properly, thus compromising cell survival.  Work 
is ongoing in the laboratory to test these hypotheses and better understand how these mutations 
impact tTG function in cells and contribute to the observed changes in cellular outcomes.  
The role of tissue transglutaminase in apoptosis 
 Ten years ago, the perception of tTG’s role in biology was very different than what it is 
today.  tTG was originally studied for its role in promoting apoptosis, as researchers observed 
that increased tTG expression was correlated with cells undergoing cell death (33-36).  One of 
the first examples of this was found using models of induced liver hyperplasia, which mimic the 
natural cycle of proliferation and cell death that occurs when the liver is exposed to an acute 
injury (37).  In this model, rat livers are injected with a dose of lead nitrate which triggers the 
proliferation of hepatocytes to compensate for the injured cells.  After 3-4 days, the level of lead 
nitrate diminishes and programmed cell death occurs to restore the liver to its normal mass.  
12
Examination of tTG in this model revealed that its expression and activation were up-regulated, 
specifically during the programmed cell death stage, and that it was an important contributor to 
the apoptotic response (38).  In other studies, this correlation between increases in tTG 
expression and the induction of apoptosis was thought to be the result of enhanced tTG 
crosslinking activity resulting in protein aggregation, or in some cases, impaired mitochondrial 
function or enhanced oxidative stress (35,39).  
 Around the same time that tTG was being linked to the apoptotic response during liver 
hyperplasia, researchers were also finding a unique connection between tTG and certain 
neurodegenerative diseases including Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s 
disease (HD).  These disorders are characterized by the accumulation of protein aggregates 
which promote neuronal dysfunction and death (40).  In each of these diseases a specific 
protein(s) is mutated in such a way as to promote its aggregation including β-amyloid and Tau in 
AD, α-synuclein in PD, and the Huntington protein in HD.  Surprisingly, all of these proteins 
were identified as potential substrates of tTG in vitro and tTG was shown to be a component of 
the aggregates that form in the brains of patients afflicted with these disease states (19-21,41,42).  
Perhaps the best studied examples involve those proteins that undergo poly-glutamine 
expansions, such as the Huntington protein.  Given tTG’s ability to crosslink glutamine-
containing proteins, these seemed to be ideal candidates for tTG’s transamidation activity.  
Normal individuals have between 6 and 39 glutamine (CAG) repeats within the amino terminus 
of the Huntington protein, whereas individuals with Huntington’s disease have more than 39 
CAG repeats in the Huntington protein, with some of the most severe cases reaching glutamine 
expansions of more than 60 residues (43).  Researchers showed that the levels of tTG expression 
were elevated in cells expressing a mutant form of the Huntington protein and that tTG 
13
preferentially crosslinks the poly-glutamine-expanded form of Huntington (a protein with more 
than 39 glutamine residues) to a much greater extent than the wild-type protein (a protein with 6-
39 glutamine residues), thus causing significant protein aggregation (41,44).  Based on these 
findings, many researchers became interested in tTG and how its activity toward these particular 
substrates could impact neurodegenerative disorders. 
In addition to these proteins serving as possible substrates for tTG, its expression and/or 
transamidation activity were shown to be up-regulated in the brains of individuals affected by 
these neurodegenerative diseases (19,20,41).  Researchers discovered that inhibition of tTG’s 
crosslinking activity reduced protein aggregation and extended the lifespan of affected mice in 
models of PD and HD (45-47).  Cumulatively, these studies portrayed a role for tTG in 
crosslinking specific protein substrates to drive protein aggregation and cell death.  Moreover, 
they laid the foundation for future studies to determine whether tTG may represent a valid target 
for therapeutic intervention against neurodegenerative diseases characterized by protein 
aggregation. 
The role of tissue transglutaminase in cellular differentiation  
 While much of the early work on tTG suggested that it was important for triggering cell 
death, other laboratories including our own, became interested in the idea that tTG may also be 
important in promoting cellular differentiation.  Several studies have shown that tTG expression 
is up-regulated during cellular differentiation (9,14,48).  For example, treatment of SH-SY5Y 
neuroblastoma cells with retinoic acid (RA), a natural compound known to induce the 
differentiation of these cells into neurons, resulted in increased expression of tTG and its 
associated transamidation activity (48).  Two pieces of evidence suggested that this increase in 
tTG expression and activation were not just casual markers of cellular differentiation, but instead 
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played critical roles in mediating this outcome.  First, it was shown that inhibiting tTG 
transamidation activity, by stably expressing a transamidation-defective mutant of tTG (tTG 
C277S) in cells or by knocking-down tTG expression using an anti-sense construct, prevented 
RA from inducing differentiation.  Additionally, ectopic expression of tTG in SH-SY5Y cells 
was sufficient to mimic the effects of RA and induce neurite outgrowth, an indicator of cellular 
differentiation.  These results suggested that the up-regulation in tTG expression and 
transamidation activity was responsible for RA’s ability to promote cellular differentiation, 
highlighting the possibility that tTG may play an important role in promoting cellular processes 
besides apoptosis. 
It was about this same time that our laboratory began evaluating the impact of natural and 
synthetic retinoids on cancer progression, as there was much interest in the use of these agents as 
potential cancer therapies due to their ability to cause cells to differentiate.  Using human HL60 
leukemia cells as a model system, we showed that RA treatment caused the cells to differentiate 
and inhibited their growth, whereas treatment of the cells with a synthetic analog of RA known 
as N-(4-hydroxyphenol)retinamide (HPR) potently induced cell death (14).  The only difference 
between these two retinoids is the addition of a phenol ring to the carbon backbone of RA.  An 
interesting clue as to how these retinoids gave rise to different cellular outcomes (cell 
differentiation versus cell death) came from the finding that long-term (2 days) pre-treatment of 
HL60 cells with RA was sufficient to protect the cells from HPR-induced apoptosis (14).  This 
raised the possibility that RA treatment likely caused changes in the expression of certain genes 
which could protect cells against HPR-mediated apoptosis.  Indeed, this turned out to be the case, 
as tTG was identified as the gene specifically up-regulated by RA to protect cells from HPR-
induced cell death.  Moreover, ectopic expression of tTG in HL60 cells was as efficient as RA 
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treatment at protecting cells from HPR-induced apoptosis, and blocking tTG activity with MDC, 
converted RA from an inducer of cellular differentiation into a cell death factor.  Thus, these 
studies not only linked tTG expression and activation to the induction of cellular differentiation, 
but also showed for the first time that in certain cellular contexts tTG up-regulation can help 
protect cells against apoptotic challenges. 
The role of tissue transglutaminase in cell survival 
 These two opposing roles for tTG, one in promoting apoptosis in some cellular contexts, 
while protecting cells undergoing differentiation from cell death in others, was emerging while 
other groups were starting to explore the influence of tTG in human cancer progression.  
Unexpectedly, tTG expression and/or its transamidation activity were found to be up-regulated in 
a number of different types of human cancer including breast, brain, pancreatic, and ovarian 
cancer (17,49-52).  In particular, the expression and activation of tTG is most elevated in those 
cancers that are highly aggressive, metastatic, and chemo-resistant (17,50,53-55).  Thus, given 
the protective role that tTG plays during cellular differentiation, the obvious question that arose 
was whether tTG would have a similar protective role in a cancer cell.  
 Indeed, it was shown that tTG could contribute to the survival of human cancer cells 
challenged with various stress conditions.  For example, MDA-MB231 cells, an aggressive 
human breast cancer cell line, were shown to express inordinately high levels of tTG and 
exhibited constitutive transamidation activity.  These cells grew at a rapid rate and were known 
to be resistant to several traditional chemotherapeutic agents, including doxorubicin.  However, 
upon knocking-down tTG expression using siRNAs or inhibiting its crosslinking activity using 
the tTG-specific inhibitor, monodansylcadaverine (MDC), these cells became sensitized to 
treatment with doxorubicin and showed enhanced apoptosis (53,56).  
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An analogous study conducted in ovarian cancer cells investigated the role of tTG in the 
development of resistance to another chemotherapeutic agent, cisplatin.  Researchers had 
previously found that tTG expression and activity was up-regulated in over 70% of ovarian 
tumor samples that were analyzed (50).  Based on this, they then went on to show that those 
ovarian cancer cell lines with the highest level of tTG expression were also the most resistant to 
cisplatin (54).  Knocking-down tTG expression using an anti-sense construct or inhibiting its 
transamidation activity with a recently generated inhibitor, KCC009, sensitized the cells to 
cisplatin, thus confirming what had been shown earlier in MDA-MB231 cells, namely that tTG 
protects cells from apoptotic challenges and may be important in the development of chemo-
resistance. 
In addition, tTG was shown to play an important role in promoting the epidermal growth 
factor (EGF)-stimulated growth and survival of cells.  The EGF receptor is a well-studied cell 
surface receptor tyrosine kinase, whose signaling capabilities have been intimately linked to 
oncogenesis (57,58).  The EGF receptor is over-expressed in a number of different types of 
human cancer, and upon binding ligand (EGF) it becomes activated and sends aberrant signals 
that trigger cancer progression.  Thus, it is not surprising that the EGFR has been major target for 
therapeutic intervention for many years.  The interplay between EGF receptor signaling and tTG 
was first discovered in human SKBR3 breast cancer cells, where tTG expression was increased 
in response to EGF treatment from nearly undetectable levels to levels that were readily 
detectable by Western blot analysis (53).  These cells also grew and survived serum-starvation-
induced apoptosis better when treated with EGF.  Importantly, these effects were shown to be 
dependent on tTG, as inhibition of tTG’s crosslinking activity using MDC prevented the growth 
advantage and protective effect afforded to SKBR3 cells by EGF stimulation.  Likewise, EGF 
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stimulation of two other human breast cancer cell lines, BT-20 and MDA-MB468 cells, caused 
an up-regulation of tTG expression suggesting that the up-regulation and activation of tTG may 
be a fundamental mechanism by which EGF protects cells, especially cancer cells, against 
apoptotic challenges (27,53). 
How is tTG able to impact cell viability?  Given the evidence that tTG’s transamidation 
activity was important for promoting cell survival, it was logical to suspect that tTG must be 
crosslinking a particular substrate to impact cell viability.  While many efforts have been made to 
identify such proteins, determining those that are physiologically relevant has proven to be a 
challenging task.  However, two protein substrates of tTG have been discovered in recent years 
which may have a critical impact on cancer cell survival.  One such substrate is caspase-3, a 
cysteine protease that is part of the conventional apoptotic signaling cascade (59).  In an actively 
growing cell, caspase-3 exists as a pro-caspase, or inactive enzyme.  However, if a cell should 
decide to undergo programmed cell death (i.e. in the face of an extreme cellular insult that has 
damaged the cell beyond repair), caspase-3 becomes cleaved to yield an active cysteine protease 
which then cleaves several essential proteins necessary for cell survival, thus resulting in cell 
death.  The finding that tTG could crosslink caspase-3 came from a study that was investigating 
how Bax-deficient HCT-116 colon cancer cells were able to survive amidst treatment with 
thapsigargin (THG), an inhibitor of the endoplasmic reticulum calcium ATPase (60).  The study 
found that THG treatment resulted in the formation of higher molecular weight forms of pro-
caspase-3.  Knocking-down tTG using siRNAs or inhibiting its transamidation activity using 
MDC not only blocked the THG-induced formation of these higher molecular weight species of 
pro-caspase-3, but it also sensitized the cells to apoptosis.  These results indicate that THG 
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treatment of HCT-116 cancer cells results in the up-regulation and activation of tTG, which in 
turn protects cells from THG-triggered apoptosis by crosslinking and inactivating caspase-3.  
 In addition to caspase-3, tTG was also found to crosslink IκBα, the major negative 
regulator of NF-κB (61).  NF-κB is a well-studied transcription factor which is sequestered in the 
cytosol through its association with its regulatory subunit IκBα (62).  However, upon growth 
factor treatment or in response to cellular stresses, IκBα is phosphorylated by the IκB kinase 
(IKK) complex, an event which targets it for ubiquitination and subsequent degradation in the 
proteasome.  This, in turn, frees NF-κB to translocate to the nucleus where it enhances the 
transcription of various genes involved in promoting cell growth and survival.  In recent years, 
NF-κB has become recognized as an important contributor to tumorigenesis, as its aberrant 
activation has been detected in a number of different cancer types (62-66).  One mechanism by 
which NF-κB is activated in cancer cells involves tTG and its ability to crosslink IκBα (61).  The 
observation that increases in tTG expression correlated with high NF-κB activity was made in 
several different cancer cell lines including, MDA-MB231 breast cancer cells, A375 malignant 
melanoma cells, and Panc-28 pancreatic cancer cells.  It was then shown that knocking-down 
tTG or inhibiting its transamidation activity in each of these cell lines resulted in a significant 
reduction in NF-κB activity, implying that NF-κB activation was functionally dependent on tTG.  
The authors went on to show that tTG could crosslink IκBα into higher molecular weight species 
of the protein both in vivo and in vitro.  Moreover, recombinant IκBα crosslinked by tTG 
displayed weaker binding to NF-κB than non-crosslinked IκBα, implying that tTG works to 
inactivate the regulatory role of IκBα by crosslinking it, rendering NF-κB consitutively active.  
This connection between tTG and NF-κB activation has been observed by other groups in 
ovarian and breast cancer cells as well (54,67).  However, the mechanism through which tTG 
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activates NF-κB does not always appear to involve the crosslinking of IκBα into a non-functional 
oligomer.  Rather, in some cases, increases in tTG expression appear to lead to decreases in the 
expression of IκBα, while knocking-down tTG using siRNAs or inhibiting its crosslinking 
activity enhances expression of IκBα, which then down-regulates NF-κB activity (54).  How tTG 
regulates the expression of IκBα is currently unknown, but recent evidence suggesting that tTG 
can localize to the nucleus and influence the expression of metabolic enzymes, opens the door to 
the possibility that tTG may directly influence IκBα expression (68,69).  However, at least one 
other study has described another potential substrate for tTG, the tumor suppressor von Hippel-
Lindau (VHL), which, when post-translationally modified by tTG, may lead to NF-κB activation 
(67).  VHL is part of an E3 ubiquitin ligase complex which targets hypoxia inducible factor 1 
alpha (HIF1α) for degradation by the proteasome (70,71).  Loss of VHL results in the 
accumulation of HIF1α and increased signaling through transforming growth factor alpha 
(TGFα) and EGF, resulting in NF-κB activation.  At least one group has shown that tTG drives 
the formation of VHL polymers which are subsequently targeted for degradation by the 
proteosome (67).  Thus, tTG’s ability to limit the expression of VHL would allow for enhanced 
NF-κB signaling.  Overall, these findings depicted in Figure 1.3, show that tTG is commonly up-
regulated and activated in cancer cells to promote cell viability and may achieve this through 
multiple mechanisms such as inactivating components of the apoptotic machinery, or activating 
keys nodes of various signaling networks.  
The role of tissue transglutaminase in aberrant cellular growth 
 In addition to its role in protecting cells from apoptotic challenges, there is evidence to 
suggest that tTG may also contribute to malignant transformation by promoting several other 
cellular behaviors commonly exhibited by cancer cells.  One such example was discovered in our 
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 Figure 1.3 tTG promotes cell survival through various mechanisms.  One of tTG’s 
primary roles in promoting cancer progression is to enhance cell survival. tTG is able to 
crosslink Caspase-3 and inactivate it, thus preventing cells from undergoing programmed cell 
death. In other cellular contexts, tTG has been shown to regulate IκBα. tTG has been shown 
to directly influence IκBα expression levels through a poorly understood mechanism. 
However, tTG can also crosslink IκBα into higher order oligomers which prevents it from 
binding to NF-κB and inhibiting the ability of NF-κB to function as a transcription factor. 
Both of these mechanisms lead to the constitutive activation of NF-κB. Similarly, tTG has 
been shown to crosslink the tumor suppressor, von Hippel Lindau (VHL) and inactivate it, 
leading to NF-κB activation. All of these are mechanisms by which tTG enhances cell 
survival. 
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laboratory using the human breast cancer cell line, SKBR3.  As mentioned previously, EGF 
treatment induces tTG expression and activation in these cells, as well as other breast cancer 
cells, including BT-20 and MDA-MB468 cells, and this up-regulation in tTG 
expression/activation is critical for promoting chemo-resistance (53).  To learn more about how 
EGF treatment causes an up-regulation of tTG expression, our laboratory transiently transfected 
SKBR3 cells with plasmids encoding constitutively active (or fast cycling) mutant forms of 
small GTPases which are known to be downstream effectors of the EGF receptor including Ras 
(G12V), RhoA (F30L), and Cdc42 (F28L) (27).  Interestingly, while introduction of any one of 
these activated small GTPases alone in the cells was insufficient to cause an up-regulation of 
tTG expression, combinations of these plasmids, such as Ras (G12V) with either RhoA (F30L) 
or Cdc42 (F28L), resulted in a marked increase in tTG expression.  Thus, these results suggested 
that the induction of tTG expression by EGF requires inputs from multiple signaling pathways 
such as the Ras and Rho/Cdc42 pathways.  Importantly, these findings also correlate with the 
observation that the highest levels of protein expression of tTG often occur in the most 
aggressive, metastatic, and invasive tumors (i.e. those that have acquired many mutations in 
signaling proteins and likely display persistent activation of multiple signaling pathways) 
(17,50,53-55).  
With a preliminary understanding of the signaling events that are responsible for 
increasing tTG expression levels in cancer cells, the next goal was to determine how tTG 
expression impacts the behavior of the cells.  We found that ectopic expression of tTG in these 
cells is sufficient to mimic the effects of EGF and leads to enhanced anchorage-independent 
growth, as read-out by soft agar colony formation (an in vitro measure of tumorigenicity) (27).  
Interestingly, ectopic expression of a transamidation-defective form of tTG in which the active 
23
site cysteine has been mutated to a valine (C277V) was unable to induce anchorage-independent 
growth like wild-type tTG.  Examination of the activities of various signaling proteins in cells 
over-expressing tTG led to the discovery that tTG stimulates the activation of the non-receptor 
tyrosine kinase c-Src.  Moreover, inhibition of Src activity using the inhibitor, PP2, eliminated 
tTG-promoted soft agar growth, thus confirming this as the mechanism by which tTG transforms 
these cells.  Further investigation revealed that wild-type tTG, but not a transamidation-defective 
form of tTG (tTG C277V), binds Src and the intermediate filament, keratin 19 in SKBR3 cells, 
resulting in the formation of a ternary complex which is likely responsible for relieving the auto-
inhibition of Src and allowing it to open and become an active kinase.  This was the first clue 
that tTG may potentially act as a scaffold to regulate signaling proteins within the cell that are 
important for cellular transformation. 
 In addition, our laboratory discovered a unique way in which tTG can help drive 
progression of the malignant state, namely through its ability to be released from cells in novel 
cellular structures called microvesicles (72).  Microvesicles are small vesicle compartments that 
arise independently of the classical secretion pathway (i.e. ER-Golgi trafficking) and appear to 
bud directly from the plasma membranes of various cancer cells (73,74).  They are believed to 
represent a novel form of cell-cell communication, as they can be released from one cell and 
taken up by neighboring cells.  Their contents include some very interesting and important cargo 
including cell surface receptors (i.e. the EGF receptor), metabolic proteins, molecular 
chaperones, RNA transcripts, and microRNAs (72-76).  In the case of cancer cells shedding 
microvesicles, it is thought that the transfer of this cargo is important for re-programming 
recipient cells in ways that help drive the oncogenic state.  For example, if the recipient cell 
happens to be another cancer cell, the microvesicles can stimulate their growth and survival 
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(75,76).  Moreover, microvesicles have also been found in the circulation of cancer patients 
where they have been recently suggested to play a role in the establishment of the pre-metastatic 
niche (75-77).  Thus, microvesicles can contribute to primary tumor growth, as well as promote 
metastasis.  
Our laboratory showed that certain cancer cell lines, such as HeLa cervical carcinoma 
cells, require EGF treatment to induce the formation of microvesicles, whereas other more highly 
aggressive cancer cells such as MDA-MB231 breast cancer cells and U87 glioblastoma cells 
constitutively generate microvesicles (72).  When these microvesicles were collected and added 
to normal (non-transformed) NIH3T3 fibroblasts, the cells started to behave like cancer cells, as 
evidenced by their acquired ability to form colonies in soft agar compared to the control NIH3T3 
fibroblasts not treated with microvesicles.  Proteomic analysis of the contents of these 
microvesicles from MDA-MB231 cells and U87 cells led to the discovery that not only was tTG 
a major protein component, but that its primary extracellular binding partner, fibronectin, was 
one of the most abundant proteins in the microvesicles.  This prompted our laboratory to look at 
whether tTG and fibronectin could be working together to mediate the transforming activity of 
these microvesicles.  Indeed, it was shown that in the microvesicles, tTG crosslinked fibronectin 
and that the interaction of the microvesicle-associated, cross-linked fibronectin with recipient 
cells resulted in enhanced integrin signaling and the induction of cellular transformation.  
Treatment of these microvesicles with inhibitors against tTG crosslinking activity or with an 
RGD peptide which blocks the ability of fibronectin to bind to integrins, eliminated the 
transforming potential of the microvesicles.  Thus, these results demonstrate a unique way in 
which tTG influences cellular transformation, namely through its role in enabling microvesicles 
to dock onto neighboring cells to enhance their integrin-coupled signaling activities. 
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The role of tissue transglutaminase in cell migration 
  The ability of cells to migrate is an important feature for many aspects of biology 
including embryonic development, tissue repair, and immune responses (78-82).  Moreover, it is 
a cellular process often studied in human cancer because its de-regulation is important for 
allowing aggressive cancer cells to acquire enhanced invasive and metastatic potential (83,84).  
Cell migration is regulated through the coordination of signaling and cytoskeletal proteins which 
work together to shape the cell and direct its movement.  For directional cell migration to occur, 
a cell must undergo polarization to establish a front or leading edge of the cell and a back or 
trailing edge (85), as diagrammed in Figure 1.4.  At the leading edge, actin polymerization 
results in membrane protrusions which extend the cell in the direction of movement.  New 
contacts are made between these protrusions and the underlying substrate, thus giving the cell an 
adhesive capability for movement.  However, in order for the cell to move, these changes at the 
leading edge must be coupled with contraction of the actomyosin cytoskeleton and severing of 
the previously established adhesions.  The modifications at the trailing edge will then allow the 
cell to detach from its substrate, retract, and pull the cell body toward the leading edge. 
 Many proteins have been shown to play a role in cell migration, including the classic 
small GTPases, Cdc42, Rac, and Rho (86,87).  It has been well-established that Cdc42 plays a 
key role in maintaining cell polarity and helps to recruit membrane/signaling proteins to the 
leading edge to propel the cell forward.  Rac also localizes to the leading edge where it promotes 
actin polymerization; whereas Rho can be found at the rear of the cell where it functions to 
facilitate retraction. 
 Cell migration is a normal process that cells undergo during development or other times 
to maintain tissue homeostasis.  However, aberrant cell migration is a key contributing factor to 
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 Figure 1.4 Structure of a migrating cancer cell. In order for directional cell migration to 
occur, a cell must become polarized in such a way as to establish a front or leading edge of 
the cell and a back or trailing edge of the cell. Actin polymerization at the leading edge is 
responsible for extending the cell in direction of movement, whereas actin stress fiber 
formation facilitates retraction at the trailing edge to allow the cell to detach and move 
forward. Rac localizes to the leading edge to facilitate actin polymerization. Cdc42 localizes 
to the cytoplasm and leading edge and plays a role in maintaining cell polarity during 
migration. Rho can be found at the trailing edge where it promotes retraction of the actin 
stress fiber network. 
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the metastatic and invasive potential of human cancer cells.  For cancer cells to metastasize to 
other tissues, several steps must take place (88).  First, cells must migrate from the site of origin 
and acquire the ability to invade through the tissue.  They undergo intravasation and enter into 
the vasculature, followed by circulation through the bloodstream or the lymphatic system.  The 
cells then complete extravasation where they exit the vasculature and colonize a secondary site.  
Most of the research regarding this process has been devoted to understanding the first step, 
namely how cells acquire the ability to migrate and invade.  
 One of the first studies linking tTG to cell migration was in 2006 when researchers were 
generating MDA-MB231-derived sub-lines on the basis of their differential expression of tTG 
(56).  They discovered that the MDA-MB231 sub-line expressing high levels of tTG showed 
enhanced cell attachment and spreading on fibronectin-coated surfaces, compared to another sub-
line which did not express tTG.  In addition, tTG was shown to localize along the plasma 
membranes of these cells where it associated with β1, β4, and β5 integrins.  Integrins are trans-
membrane receptors which coordinate interactions between the extracellular matrix and the actin 
cytoskeleton during cell migration (89,90).  Upon ligand binding, integrins transduce signals 
from the cell surface to adhesion complexes resulting in the activation of the Rho family of 
GTPases which regulate actin dynamics to promote cell motility.  Other studies confirmed these 
initial findings by demonstrating that tTG can bind to integrins to mediate the interaction 
between integrins and fibronectin and enhance cell adhesion and migration (50,91,92).  The 
ability of tTG to interact with integrins and serve as a co-receptor for fibronectin did not require 
its crosslinking activity, given that there was no difference between wild-type tTG and the 
transamidation-defective form of tTG (tTG C277S) in assays of cell adhesion and migration (92).  
However, other groups went on to show that tTG’s transamidation activity could be important 
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for integrin signaling in hepatocytes and osteoblasts, as tTG can crosslink fibronectin into higher 
molecular weight polymers (93,94).  They demonstrated that the crosslinked form of fibronectin 
enhanced integrin signaling and led to increased cell attachment. 
 Our laboratory demonstrated the importance of tTG in cell migration when analyzing 
EGF-receptor signaling in HeLa cervical carcinoma cells (13).  Antonyak et al. found that 
ligand-induced EGF receptor activation results in the stimulation of tTG’s crosslinking activity 
and causes tTG to localize to the plasma membranes of migrating cells, specifically along their 
leading edges.  This led to studies examining whether tTG might be important for cell migration 
and indeed, it was found that knocking-down tTG using siRNAs or inhibiting its transamidation 
activity using MDC, impaired the EGF-dependent migration of HeLa cells.  This then raised the 
question of how EGF treatment could impact tTG activity and direct its localization to leading 
edges.  By generating HeLa cell lines stably expressing the vector only or an activated form of 
Ras (H-Ras G12V), Antonyak et al. were able to show that the EGF receptor signaled through 
Ras to direct these changes in tTG activity and localization, since tTG was constitutively 
activated and localized to the leading edges of the oncogenic-Ras-expressing cells.  In order to 
determine which signaling protein was mediating signals from Ras to tTG, a number of well-
known signaling networks were targeted with various inhibitors to examine the effects on tTG’s 
activity and localization.  Interestingly, of the inhibitors tested, only a c-Jun-N-terminal kinase 
(JNK) inhibitor was effective at blocking tTG activity and localization to the leading edges of 
migrating cells.  While these findings argued that tTG plays an important role in EGF-driven cell 
migration, several questions remain regarding the mechanistic details for how EGF receptor 
signaling through Ras and JNK can direct these changes in tTG’s activity and localization and 
why these changes are important for cell migration.  My first data chapter will shed more light on 
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this process by identifying a novel mechanism regulating tTG’s localization at the leading edge. 
 In addition to these studies, other labs have been investigating tTG for its contribution to 
an early step in the cancer cell migration process, namely the epithelial-to-mesenchymal 
transition (EMT).  EMT describes a series of changes that a polarized epithelial cell undergoes to 
transform into a mesenchymal cell (95).  This process is characterized by degradation of the 
cell’s basement membrane which allows the cell to acquire a less-structured morphology and 
migrate away from its site of origin.  Concurrent with this is the acquisition of more invasive 
characteristics, enhanced motility, and increased generation of extracellular matrix components.  
While EMT can be found as a normal part of development and tissue repair, it is more often 
associated with cancer cells as they acquire more metastatic and invasive phenotypes.  In these 
cells, growth factor-induced signaling drives the enhanced expression of EMT-associated 
transcription factors including, Snail, Slug, Twist, zinc finger E-box binding homeobox 1 (Zeb1), 
and FoxC2.  Many of these transcription factors act as transcriptional repressors of E-cadherin; 
thus, their increased expression results in a loss of E-cadherin expression.  A “cadherin switch”, 
whereby E-cadherin expression is lost in exchange for an increase in N-cadherin expression, is 
one of the hallmarks of EMT. 
 The investigation into tTG’s role in ovarian cancer EMT and tumor metastasis began 
with the observation that tTG mRNA levels were increased in ovarian tumor tissues compared 
with surface epithelial cells from the normal ovary (96).  These initial findings led researchers to 
examine whether tTG was important for cell adhesion and directional cell migration.  Stable 
knock-down of tTG in SKOV3 ovarian cancer cells reduced cell adhesion and impaired their 
ability to migrate (50).  When these cells were injected into nude mice, it was determined that 
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stable knock-down of tTG led to less tumor dissemination compared to cells expressing the 
vector alone.  Thus, these findings suggest that tTG contributes to ovarian tumor metastasis. 
 These researchers took their work a step further showing that the reason tTG was 
important for metastasis was because of its role in promoting EMT (97).  Specifically, ovarian 
cancer cells expressing tTG adopt a mesenchymal phenotype and are more invasive than their 
counterparts which do not express tTG.  This was found to be the result of tTG activating NF-
κB, which causes the transcriptional up-regulation of Zeb1, a transcriptional repressor of E-
cadherin, leading to a cadherin switch and EMT.  Given the links between TGF-β signaling and 
EMT, this group also investigated whether TGF-β could regulate tTG expression in the context 
of ovarian cancer.  They found that secreted TGF-β did induce the expression of tTG in ovarian 
cancer cells, primarily through a Smad2/3-dependent mechanism, and that TGF-β treatment was 
sufficient to induce the EMT phenotype as read-out by decreased E-cadherin expression and 
increased expression of N-cadherin and Zeb1 (98).  Interestingly, ovarian cancer cells which 
disseminate from the primary tumor to metastasize to distinct sites for secondary tumor 
formation form cell aggregates known as spheroids.  This aggregation allows cancer cells to 
circulate while protecting them from environmental stresses during metastasis.  These spheroids 
have been shown to possess characteristics similar to stem cells (sometimes called ovarian 
cancer initiating cells, OCIC), and express representative stem cell markers including, CD44 and 
CD117.  To determine whether TGF-β treatment and the resulting induction of tTG expression 
was important for this stem cell population, investigators quantified CD44+/CD117+ populations 
in ovarian cancer cells which either expressed tTG for failed to express it.  They found that in 
cells lacking tTG, the OCIC population was significantly smaller, compared with cells which 
express tTG.  Moreover, expression levels of other stem cell-specific transcription factors 
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including Nanog, Oct3/4, and Sox-2 were also increased in cells with higher tTG expression.  
Thus, these findings demonstrate that TGF-β regulation of tTG expression may be important for 
driving EMT and contributing to the stem cell population which drives metastasis. 
Concluding Remarks 
 This introduction has described much of the research performed on tTG, beginning with 
some of the early studies that linked increases in tTG expression and crosslinking activity to the 
induction of apoptosis, especially in the context of neurodegenerative diseases (19-21,33-36).  
These studies were followed by a series of findings that revealed tTG can also play a protective 
role and prevent cells from undergoing apoptosis during cellular differentiation (9,14,48).  
Around this time, researchers were discovering that tTG expression and/or activation were up-
regulated in various types of human cancer, which led to the question: Does tTG participate in 
malignant transformation?  We now know that tTG contributes to a number of cancer cell 
phenotypes including promoting cell growth, cell survival, chemo-resistance, EMT, and cell 
migration and invasiveness (13,27,50,52-56,61,97).  All of these roles are highlighted in Figure 
1.5.  Studies have revealed that tTG is able to function inside the cell, at the cell membrane, or 
even upon its release from cells associated with microvesicles.  As a result, my thesis work has 
focused on learning more about how tTG impacts these aspects of cancer progression, in 
particular cell migration and cell survival. 
 Chapter 2 describes work that builds upon our laboratory’s initial findings that tTG is 
important for the EGF-dependent migration of HeLa cervical carcinoma cells, and the 
constitutive migration of the more aggressive breast cancer cells, MDA-MB231 cells (13).  In 
HeLa cells, EGF treatment activates tTG and induces a change in the sub-cellular localization of 
tTG, resulting in its accumulation along the leading edges of actively migrating cells.  In Chapter 
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Figure 1.5 tTG promotes several aspects of oncogenesis. To date, the research performed 
on tTG in the context of human cancer has revealed several roles for tTG in promoting cancer 
progression. tTG has been shown to regulate cell growth and survival, as well as protect cells 
faced with apoptotic challenges such as chemotherapeutic agents from undergoing cell death. 
In addition, tTG has been shown to play a key role in the acquisition of metastatic and 
invasive capabilities, and may facilitate EMT during this process. 
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2, I set out to learn more about how tTG is localized to leading edges and evaluate its importance 
for cell migration.  Interestingly, we discovered that a small population (~10%) of tTG in HeLa 
cells is constitutively associated with the plasma membrane and that this membrane-associated 
population is activated and recruited to leading edges in an EGF-dependent manner.  
Immunoprecipitations of tTG from the membrane fractions of HeLa cells treated with EGF 
revealed that tTG binds members of the Hsp70 family of molecular chaperones.  tTG and Hsp70 
co-localize to the leading edges of migrating cells and inhibition of Hsp70’s chaperonin activity 
specifically blocks Hsp70 and tTG from localizing to the leading edges of migrating cells and 
also inhibits cell migration.  Thus, these findings suggest that Hsp70 facilitates tTG’s 
localization to the leading edges of actively migrating cells and that this localization is critical 
for the EGF-dependent migration of HeLa cells and the constitutive migration of MDA-MB231 
cells. 
 In Chapter 3, the focus of my work was shifted toward trying to understand how 
expression of tTG in a normal (non-transformed) cellular background would influence various 
aspects of transformation.  The goal for this study was to learn more about the intrinsic ability of 
tTG to promote cellular transformation, versus its ability to cooperate with oncogenic proteins in 
cancer cells to achieve the malignant state.  Using NIH3T3 fibroblasts stably expressing the 
vector alone or a Myc-tagged form of wild-type tTG, we found that tTG promotes cell survival 
by activating the PI3-kinase/mTOR/p70 S6-kinase pathway.  We discovered that tTG forms a 
‘signaling complex’ with c-Src and PI3-kinase and that inhibition of tTG or Src perturbs 
complex formation and prevents tTG from activating the PI3-kinase signaling pathway.  
Activation of this pathway is critical for tTG’s ability to enhance cell viability as inhibition of 
any component of this pathway including Src, PI3-kinase, and mTOR, completely ablates the 
36
protective effect of tTG against apoptosis.  Thus, this study suggests that a primary role for tTG 
alone may be to regulate cell survival.  Moreover, these findings give us reason to believe that 
tTG is a valid target for cancer therapy. 
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CHAPTER 2 
 
A Unique Role for Heat Shock Protein 70 and its Binding Partner Tissue Transglutaminase 
in Cancer Cell Migration* 
 
Introduction 
 Cell migration is a highly complex, multi-step process that is carried-out by virtually all 
cell types at some point during their lifetime and it underlies a number of important biological 
outcomes that range from embryonic development to immune responses and tissue 
repair/regeneration (1-5).  It is also a cellular function that is frequently targeted for deregulation 
in human cancers, as acquiring the ability to migrate aberrantly is a crucial step in the 
development of the invasive and metastatic phenotypes exhibited by advanced stage cancers 
(6,7).  Although many important questions regarding how migration is regulated in different 
cellular contexts remain unanswered, the general process of cell migration is fairly well 
established.  Common to all forms of directional cell migration is the formation of a polarized 
cell, where the asymmetric distribution of signaling proteins, phospholipids, and cytoskeletal 
components gives rise to a cell with both leading and trailing edges (8).  The leading edge is 
characterized by Arp2/3-driven actin polymerization and plasma membrane protrusions which 
extend from the cell body in the direction of movement.  These membrane protrusions then make 
new contact points between a cell and its underlying substrate, providing the necessary adhesion 
that a cell needs to move forward.  However, in order for a cell to successfully migrate, 
immediately following the formation of new adhesion sites along the leading edge, changes at 
                                                            
* Published previously as Boroughs LK & Antonyak MA, et al. (2011) J Biol Chem 286:27094-37107. 
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the trailing edge of the cell must also occur.  In particular, contraction of the acto-myosin 
cytoskeleton and the disassembly of established cell adhesion sites at the trailing edge take place 
in order to allow the back end of a migrating cell to detach from its substrate, retract, and then 
shift the remaining part of the cell body towards the leading edge.   
Given the connections between cell migration and numerous biological outcomes 
including the progression of certain human disease states (i.e. cancer), it is not surprising that a 
good deal of effort has been dedicated toward understanding the mechanisms that are responsible 
for regulating the ability of cells to migrate.  The induction of cell migration is typically 
triggered by growth factors and/or signals from the extracellular matrix that surrounds cells 
(9,10).  The abilities of these extracellular stimuli to induce the activation of a series of signaling 
events within target cells help coordinate the extensive remodeling of the actin cytoskeleton and 
changes in the adhesion properties of cells that are necessary for cell migration.  For example, 
stimulating the human cervical carcinoma cell line, HeLa, with EGF causes these cells to acquire 
a polarized morphology (forming both leading and trailing edges), as well as increases their 
ability to migrate and exhibit invasive activity (11). 
Among the most extensively investigated group of signaling proteins that have been 
linked to EGF-induced cell migration are members of the Rho family of small GTPases 
including Cdc42, Rho, and Rac (12,13).  Each of these highly related GTPases are regulated in a 
spatially and temporally specific manner in actively migrating cells.  Cdc42 is necessary for 
establishing and maintaining cell polarity by properly positioning the nucleus and orienting 
microtubules in the direction of cell movement, and by helping to recruit signaling and 
motor/assembly proteins to the leading edges of cells.  On the other hand, Rac and Rho act 
antagonistically toward each other, with Rac being predominantly localized to leading edges 
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where it promotes Arp2/3-dependent actin polymerization and the formation of cellular 
protrusions, whereas Rho is found along trailing edges where it participates in the contraction 
and bundling of the actin cytoskeleton. 
While several other proteins have been implicated in EGF-stimulated cell migration, the 
vast majority of these are traditional signaling proteins (i.e. Ras, PI3-kinase, PLC, ERK, and 
JNK) (7,14,15).  However, there are also a few examples of non-traditional signaling proteins 
that are important for certain types of cells to migrate.  One such example is tTG, a dual 
functioning protein that combines an ability to bind and hydrolyze GTP with an enzymatic 
transamidation activity that generates covalent crosslinks between two proteins or between a 
protein and a polyamine (16,17).  tTG is over-expressed in a significant percentage of advanced 
stage and high grade human cervical, lung, brain, prostate, and breast tumors, and its 
transamidation (crosslinking) activity has been shown to be essential for the invasive/metastatic 
behavior of highly aggressive cancer cells, such as the MDAMB231 human breast cancer cell 
line (18-21).  Recently, we showed that the stimulation of HeLa carcinoma cells with EGF 
resulted in tTG activation and its accumulation at their leading edges, whereas knock-downs of 
tTG, or exposure of the cells to the tTG inhibitor monodansylcadaverine (MDC), inhibited the 
EGF-stimulated migration and invasive activity of these cells (11).  Although these findings 
demonstrate a fundamental role for tTG, and in particular its enzymatic crosslinking activity, in 
EGF-stimulated cancer cell migration, what remains to be determined is how EGF triggers the 
accumulation of tTG at the leading edges of cells and whether this event is important for the 
ability of tTG to promote cell migration. 
In this study, we have taken an important step toward answering these questions by 
uncovering a novel connection between tTG, a component of the chaperonin network, Hsp70, 
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and the ability of human cancer cells to migrate.  We identify Hsp70 as a novel tTG-interacting 
partner, and show that the ability of plasma membrane-associated tTG to localize to the leading 
edges of EGF-stimulated HeLa cells, as well as to the leading edges of constitutively migrating 
MDAMB231 breast cancer cells, is sensitive to inhibition of Hsp70.  Importantly, we further 
demonstrate that exposure of these different cell lines to inhibitors of the ATP hydrolytic activity 
of Hsp70, while having no effect on the protein crosslinking activity of tTG, inhibits EGF-
induced HeLa cell migration and the constitutive migration normally exhibited by MDAMB231 
breast carcinoma cells.  To our knowledge, these findings show for the first time that the 
chaperonin capabilities of heat shock proteins can participate in cell migration by helping to 
target key regulatory proteins (i.e. tTG) to the leading edges of migrating cells, as well as 
demonstrate that the proper localization of tTG to leading edges is crucial for its ability to 
promote cancer cell migration.    
 
Results 
tTG is recruited to the leading edges of migrating cancer cells 
The accumulating evidence implicating tTG as an important contributor to cancer cell 
migration, invasion, and metastasis (11,19,20) prompted us to investigate further the possible 
regulatory mechanisms that underly its ability to promote cell migration.  We chose the HeLa 
cervical carcinoma cell line as our initial model system because we had previously established 
that stimulating HeLa cells with EGF induced tTG activation and showed that knocking-down 
tTG, or treatment of these cells with the tTG crosslinking inhibitor MDC, blocked their EGF-
stimulated migration and invasive activity (11).  Using scratch or wound-healing assays as a 
means to read-out the rates of cell migration, we confirmed the importance of tTG activity in 
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mediating EGF-stimulated HeLa cell migration by showing that the ability of EGF to promote 
the migration of HeLa cells, as indicated by their movement into the wound, is severely ablated 
when the cells are treated with MDC (Figure 2.1A, compare the last two images in the top 
panels).  Likewise, knocking-down tTG in HeLa cells using two different siRNAs (Figure 2.1B, 
left panels) inhibited the EGF-dependent migration of these cells (Figure 2.1B, right panels).  
However, we also noticed by immunofluorescent analysis that treating serum-starved HeLa cells 
with EGF for increasing lengths of time caused a detectable change in the subcellular distribution 
of tTG (Figure 2.1C, top row on the left).  While in untreated HeLa cells, tTG was expressed 
primarily throughout the cytoplasm, EGF treatment of the cells for as little as 1 hour caused an 
accumulation of tTG at their plasma membranes, particularly along leading edges, as indicated 
by its co-localization with sites of F-actin build-up (Figure 2.1C, middle row), as well as with the 
leading edge marker cortactin (22) (Figure 2.1D, left panels).  This effect of EGF on the 
subcellular localization of tTG persisted even after 12 hours of EGF stimulation (Figure 2.1C, 
top row), suggesting that tTG could be a leading edge-resident protein.  Consistent with this idea, 
immunofluorescence performed on serum-starved MDAMB231 breast carcinoma cells, a highly 
invasive/metastatic human cancer cell line whose constitutive migration capabilities are 
dependent on tTG as determined by MDC treatment (Figure 2.1A, compare the last two images 
in the bottom panels) and by tTG knock-down (Figure 2.1E), revealed that tTG accumulated 
along their leading edges as well (Figure 2.1C, on the right, and Figure 2.1D, on the right).  
Taken together, these findings raise the intriguing possibility that the recruitment of tTG to the 
leading edges of actively migrating cells may represent an important regulatory step underlying 
its ability to promote cell migration.  
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 Figure 2.1  tTG is localized to the leading edges of actively migrating cells and its 
crosslinking activity is necessary for cell migration.  (A) Scratch assays were performed on 
HeLa cells (top panels) and MDAMB231 cells (bottom panels) treated without (Untreated) or 
with EGF, and without or with MDC, as indicated.  MDAMB231 cells were fixed 12 hours 
after striking the wound; HeLa cells were fixed after 24 hours.  The cells were then visualized 
using light microscopy and the extent of wound closure determined.  One set of untreated 
cells was fixed immediately after striking the wound (Untreated 0 hr.) to indicate the size of 
the initial wounds.  The widths of the initial wounds are indicated by dashed lines.  (B) The 
extracts collected from HeLa cells transfected with control-RNAi, tTG-RNAi 1, or tTG-RNAi 
2 were immunoblotted with tTG and actin antibodies (left panels).  Scratch assays were then 
performed on cells transfected with the same siRNAs, treated without (Untreated) or with 
EGF.  The cells were processed as outlined in A (right panels).  (C and D) Duplicate sets of 
serum-starved cultures of HeLa cells and MDAMB231 cells were treated without (Untreated) 
or with EGF for increasing lengths of time, as indicated, and then were fixed.  (C) 
Immunofluorescence was performed on one set of the cells using a tTG antibody, rhodamine-
conjugated phalloidin (Actin), and DAPI (to stain nuclei).  (D)  Immunofluorescence was 
performed on the second set of cells using tTG and cortactin antibodies and DAPI.  
Representative fluorescent images of the cells are shown and the localization of tTG and 
cortactin at leading edges is indicated with arrows.  (E) The extracts collected from 
MDAMB231 cells transfected with control-RNAi, tTG-RNAi 1, or tTG-RNAi 2 were 
immunoblotted with tTG and actin antibodies (top panels).  Scratch assays were then 
performed on cells transfected with the same siRNAs and the cells were processed as outlined 
in A (bottom panels).   
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A plasma membrane-associated pool of tTG is trafficked to leading edges 
 In order to determine whether the localization of tTG at leading edges plays an essential 
role in cell migration, we set out to better understand how tTG accumulates at these distinct 
regions of the plasma membrane.  Based on our immunofluorescence experiments (Figures 2.1C 
and 2.1D) it appears that tTG is predominantly expressed in the cytoplasm of untreated HeLa 
cells, but can then be detected along their leading edges in response to EGF stimulation.  Thus, 
we initially suspected that the appearance of tTG at the leading edges of EGF-stimulated HeLa 
cells was an outcome of its recruitment from the cytoplasm to the plasma membrane.  To 
determine whether this was indeed the case, we examined whether the changes in the distribution 
of tTG in HeLa cells treated with EGF, as observed by immunofluorescence, could also be 
detected using a cell fractionation approach (i.e. as monitored by increases in the amount of tTG 
present in the membrane fractions collected from EGF-stimulated HeLa cells).  Serum-starved 
HeLa cells that had been left untreated, or were stimulated with EGF for 1, 3, or 12 hours, were 
collected, divided into their cytosolic and membrane fractions, and the resulting extracts were 
immunoblotted.  Figure 2.2A shows that the fractionation procedure was successful, as indicated 
by the enrichment of the plasma membrane-associated protein, fibronectin, in the membrane 
fractions, and the cytosolic protein, IκBα, in the cytoplasmic fractions (Figure 2.2A, second and 
third panels from the top, respectively).  However, when the blot was probed for tTG, we 
obtained a surprising result.  Rather than detecting increased amounts of tTG in the membrane 
fractions from the EGF-stimulated HeLa cells compared to those collected from untreated HeLa 
cells, we found that the levels of tTG were essentially equivalent (determined by densitometry to 
be 10 % ± 2.5 % of the tTG expressed in the cells)  in these different membrane fractions (Figure  
58
 Figure 2.2  A pool of tTG is constitutively associated with the plasma membrane.  
Serum-starved HeLa cells that had been treated without (0) or with EGF for increasing 
lengths of time, as indicated, were homogenized and then subjected to differential 
centrifugation to separate cytosolic and membrane fractions.  (A) The cellular fractions were 
immunoblotted with tTG, fibronectin, IκBα, and actin antibodies.  (B) The same membrane 
fractions were also assayed for tTG transamidation activity by determining the incorporation 
of BPA into lysate proteins.  (C) Actively growing HeLa cells that had been either mock 
transfected without DNA (Mock) or transfected with various Myc-tagged forms of tTG 
including wild-type (tTG WT), a transamidation-defective mutant (tTG C277V), or a GTP-
binding-defective mutant (tTG R580K), were homogenized and then subjected to differential 
centrifugation to isolate cytosolic and membrane fractions.  The fractions were 
immunoblotted with Myc, fibronectin, IκBα, and actin antibodies.  (D) Synthetic liposomes 
were prepared by extrusion and then equal amounts of this preparation were combined with 
either 5 µg recombinant tTG (tTG WT) or 5 µg bovine serum albumin (BSA).  After a 15 
minute incubation, the liposomes were pelleted by centrifugation, and the resulting 
supernatant (Sup) and liposome (Pellet) fractions were resolved by SDS-PAGE.  The gel was 
then stained with Quick Blue to detect the proteins.  A lane containing recombinant tTG (Rec. 
tTG WT) was included as a standard. 
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2.2A, top panel).  This indicated that EGF does not direct the translocation of tTG from the 
cytoplasm to the surface of HeLa cells.  Instead, it appears that a small but discrete pool of tTG  
associates with the plasma membrane in serum-starved HeLa cells (that cannot be detected by 
immunofluorescence), and is redistributed in an EGF-dependent manner such that it accumulates 
at the leading edges of cells.    
 We next examined whether EGF treatment would affect the activity of the plasma 
membrane-associated pool of tTG.  The same membrane fractions analyzed in Figure 2.2A were 
assayed for tTG-catalyzed transamidation activity, as read-out by the incorporation of BPA into 
lysate proteins.  Figure 2.2B shows that little tTG activity was detectable in the membrane 
fraction collected from serum-starved HeLa cells.  In contrast, EGF stimulation caused a marked 
increase in the crosslinking activity of the plasma membrane-associated tTG.  The increase in 
tTG activity was detectable within 1 hour of EGF treatment and was maintained, if not slightly 
enhanced, through 12 hours of continuous EGF stimulation.  It is also worth noting that the 
ability of EGF to stimulate the enzymatic crosslinking activity of the membrane-associated tTG, 
and to cause tTG to accumulate at the leading edges of HeLa cells, occur on similar time-scales 
(compare Figure 2.1C, left panel, and Figure 2.2B), highlighting the fact that both the activation 
and the localization of tTG to the leading edges of cells are tightly coupled EGF-dependent 
signaling events.  
 To gain a better understanding for how tTG associates with the plasma membrane, two 
additional experiments were performed.  In the first experiment, we examined whether the GTP-
binding capability or the transamidation activity of tTG was required for it to associate with 
plasma membranes.  Actively growing HeLa cells ectopically expressing Myc-tagged forms of 
wild-type tTG (tTG WT), or mutant forms of tTG that were defective in their abilities to either 
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catalyze the formation of protein crosslinks (tTG C277V) or to bind GTP (tTG R580K) (23,24), 
were collected and fractionated into their cytosolic and membrane components.  The resulting 
lysates were then immunoblotted with a Myc antibody to detect the different ectopically 
expressed forms of tTG.  The top panel in Figure 2.2C shows that the ectopically expressed 
transamidation-defective form of tTG (tTG C277V), and the GTP-binding-defective mutant (tTG 
R580K), were localized to the membrane fractions from HeLa cells just as efficiently as the 
ectopically expressed wild-type tTG, indicating that the ability of tTG to associate with plasma 
membranes does not require its GTP-binding or transamidation activity. 
 In the second experiment, we examined whether tTG could directly associate with plasma 
membranes or if it requires additional proteins to do so.  To address this question, we used an in 
vitro approach similar to one that was developed to examine the ability of the small GTPase 
Cdc42 to interact with synthetically-derived liposomes (25).  Purified recombinant wild-type tTG 
(tTG WT), or bovine serum albumin (BSA) serving as a control, was combined together with 
synthetically-derived liposomes whose lipid composition was similar to that of the inner leaflet 
of the plasma membrane in mammalian cells.  Following a brief incubation, the vesicles were 
pelleted by centrifugation, and then the resulting supernatants and pellets were resolved by SDS-
PAGE and stained with Quick Blue to detect the proteins.  Figure 2.2D shows that tTG has a 
relatively high affinity for lipids, as nearly all of the recombinant tTG (tTG WT) was found to 
have pelleted with the synthetic vesicles.  On the other hand, bovine serum albumin (BSA) only 
weakly pelleted with the liposomes, with most of the control protein remaining in the 
supernatant. 
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Hsp70 is a novel tTG-interacting protein 
 The findings above describe the identification and initial characterization of a plasma 
membrane-associated pool of tTG that may have important consequences for cell migration.  
However, they did not shed light on how tTG accumulates at the leading edges of migrating 
cells.  In particular, we wondered whether tTG may need to interact with another protein(s) to 
achieve this localization.  Thus, we set out to identify proteins that interacted with tTG in the 
plasma membranes from EGF-stimulated HeLa cells by mass spectrometry.  Serum-starved 
cultures of HeLa cells that had been left untreated or were stimulated with EGF for 12 hours (i.e. 
a time period that we knew to be sufficient for the accumulation of tTG at the leading edges of 
cells) were collected and their corresponding membrane fractions isolated and then subjected to 
immunoprecipitation using an anti-tTG antibody.  The resulting immunocomplexes were 
analyzed by SDS-PAGE followed by Colloidal Blue staining to detect proteins that co-
immunoprecipitated with tTG.  Whereas several proteins co-immunoprecipitated with tTG from 
the membrane fractions prepared from untreated HeLa cells, the majority of these proteins were 
not detected when tTG was immunoprecipitated from the membrane fractions derived from 
EGF-stimulated cells (Figure 2.3A).  A notable exception was a protein band with an apparent 
molecular mass of ~70 kDa (Figure 2.3A, arrow).  Since we were searching for proteins that 
would interact with tTG in EGF-stimulated cells, as candidates for helping to mediate the 
translocation of tTG to leading edges, we determined the identity of the ~70 kDa protein by mass 
spectrometry.  In fact, we found that this protein band consisted of two highly homologous and 
functionally redundant members of the heat shock protein family, namely Hsp70 and Hsc70 (26) 
(Figure 2.3B).  What makes the identification of Hsc70 and Hsp70 as novel interacting partners 
for plasma membrane-associated tTG particularly intriguing is that they were recently shown to  
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 Figure 2.3  Hsp70 interacts with plasma membrane-associated tTG.  (A) Serum-starved 
HeLa cells that had been treated without (0) or with EGF for 12 hours were homogenized and 
then subjected to differential centrifugation to isolate the membrane components of the cells.  
Immunoprecipitations with a tTG antibody (IP:tTG) were performed on the membrane 
extracts and the resulting immunocomplexes were resolved by SDS-PAGE.  The gel was then 
stained with Colloidal Blue to detect the proteins that co-immunoprecipitated with tTG.  One 
protein band (Mr ~70 kDa), denoted with an arrow, was determined to contain two isoforms of 
the heat shock protein 70 family, Hsp70 and Hsc70, by mass spectrometry.  (B) The protein 
sequences of human Hsp70 and Hsc70 are shown in gray.  The peptide fragments identified 
by mass spectrometry are shaded in black.  (C) Immunoprecipitations with a Myc antibody 
were performed on the extracts of HeLa cells ectopically expressing V5-tagged Hsc70 and 
Myc-tagged tTG, treated without (Untreated) or with EGF.  The whole cells lysates (WCL) 
and the resulting immunocomplexes (IP:Myc) were immunoblotted with V5 and Myc 
antibodies.  Non-specific mouse IgG control antibody and beads-only control 
immunoprecipitations were also performed on the extracts to show that the Hsc70-tTG 
interaction was specific.  (D) Immunoprecipitations with a Myc antibody were performed on 
the extracts of actively growing HeLa (top panels) and MDAMB231 cells (bottom panels) 
that were ectopically expressing V5-tagged Hsc70 and a Myc-tagged form of either wild-type 
tTG (tTG WT) or a transamidation-defective form of tTG (tTG C277V).  The whole cell 
lysates (WCL) and the resulting immunocomplexes (IP:Myc) were immunoblotted with V5 
and Myc antibodies.  Non-specific mouse IgG control antibody and beads-only control 
immunoprecipitations were performed on the extracts collected from HeLa and MDAMB231 
cells expressing V5-Hsc70 and Myc-tTG WT to show that the Hsc70-tTG interaction was 
specific.   
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be uniquely capable of integrating into artificial lipid bilayers, as well as into plasma membranes 
derived from cancer cell lines (27,28).  We first confirmed this interaction by performing 
immunoprecipitations with a Myc antibody on the cellular lysates from HeLa cells transiently  
co-expressing a V5-tagged form of Hsc70 and a Myc-tagged form of tTG, treated without or 
with EGF.  Figure 2.3C shows that V5-tagged Hsc70 can be co-immunoprecipitated with Myc-
tagged tTG, independent of EGF treatment.  Next we compared the ability of Hsc70 to interact 
with wild-type tTG and a transamidation defective form of tTG (C277V) by performing 
immunoprecipitations with a Myc antibody on the cellular extracts from HeLa cells (Figure 
2.3D, top panels), as well as MDAMB231 breast cancer cells (Figure 2.3D, bottom panels), that 
were transiently co-expressing a V5-tagged form of Hsc70 and a Myc-tagged form of tTG.  
Figure 2.3D shows that V5-tagged Hsc70 can be co-immunoprecipitated with Myc-tagged tTG 
(Myc-tTG WT) in each of these cell types.  Moreover, the transamidation-defective form of tTG 
(Myc-tTG C277V), when ectopically expressed in HeLa cells or MDAMB231 cells, was able to 
bind Hsc70 as efficiently as wild-type tTG, suggesting that the ability of tTG to interact with 
heat shock protein family members does not require its enzymatic transamidation activity. 
 We next used immunofluorescence approaches to determine whether Hsp70, like tTG, 
was expressed along the leading edges of migrating cells.  Our reasoning was that if the binding 
of tTG to Hsp70 family members is necessary for the recruitment and accumulation of tTG at 
leading edges, then Hsp70 and tTG should be present together at these cellular sites.  Cultures of 
serum-starved HeLa cells co-expressing V5-tagged Hsc70 and Myc-tagged tTG, that were either 
untreated or stimulated with EGF, were fixed and then stained with Myc and V5 antibodies.  The 
resulting fluorescent images showed that the V5-tagged Hsc70 was predominantly cytoplasmic 
in the serum-starved HeLa cells (Figure 2.4A, left panels).  However, following EGF- 
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 Figure 2.4  tTG and Hsp70 co-localize to the leading edges of cells.  (A) HeLa and 
MDAMB231 cells ectopically expressing V5-Hsc70 and Myc-tTG were fixed and then 
subjected to immunofluorescence using V5 and Myc antibodies and DAPI (to stain nuclei).  
Representative images of the transfectants are shown, with the co-localization of the 
ectopically expressed forms of tTG and Hsc70 at leading edges being highlighted with 
arrows.  (B) Serum-starved HeLa cells and MDAMB231 cells were treated without 
(Untreated) or with EGF for 12 hours, as indicated, and fixed.  Immunofluorescence was 
performed on the cells using tTG and Hsp70 antibodies and DAPI.  Representative images of 
the cells are shown, with the co-localization of tTG and Hsp70 at leading edges being 
indicated with arrows.   
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stimulation, the V5-tagged form of Hsc70 was readily detectable at the leading edges of these 
cells, where it co-localized with the ectopically expressed form of tTG (Myc-tTG WT). 
 An analogous experiment was then performed on the constitutively migrating 
MDAMB231 breast cancer cell line.  Consistent with the findings from HeLa cells, 
immunofluorescent analysis performed on MDAMB231 cells co-expressing V5-tagged Hsc70 
and Myc-tagged tTG showed that both of these ectopically expressed proteins co-localized along 
the leading edges of these cells (Figure 2.4A, right panels).  Endogenous Hsp70 was also shown 
to consistently localize to the developing leading edges in EGF-treated HeLa cells and in 
MDAMB231 cells (Figure 2.4B, left and right panels, respectively). 
 
Plasma membrane-associated tTG is recruited to leading edges by Hsp70 
 We next set out to determine whether Hsp70 was responsible for the accumulation of tTG 
at the leading edge.  Initially we tried to examine this by knocking-down Hsp70 family members 
from cells and seeing whether the ability of tTG to be localized to leading edges was disrupted.  
However, despite a number of attempts to knock-down Hsp70 and Hsc70, either individually or 
in combination, in HeLa cells or MDAMB231 cells (including our use of 6 different siRNAs 
targeting Hsp70 and/or Hsc70 in varying amounts for transfection), we have thus far been unable 
to significantly reduce their expression levels (data not shown).  Consequently, we turned to 
three different inhibitors of the ATP-hydrolytic activity of Hsp70, namely, myricetin, methylene 
blue, and VER 155008, to investigate the involvement of Hsp70 in targeting tTG to leading 
edges.  Figure 2.5A shows that the exposure of EGF-stimulated HeLa cells to any of these 
inhibitors was sufficient to block the ability of tTG, as well as Hsp70, to accumulate along 
leading edges.  The results of these experiments are quantified in Figure 2.5B, and show that the  
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 Figure 2.5  Inhibiting Hsp70 activity blocks the ability of tTG and Hsp70 to localize at 
leading edges.  (A) Serum-deprived HeLa cells were treated without (Untreated) or with 
EGF, -/+ myricetin, methylene blue, or VER 155008, and then immunofluorescence was 
performed on the cells using tTG and Hsp70 antibodies.  The resulting fluorescent images are 
shown with the tTG and Hsp70 at leading edges being indicated with arrows.  (B) 
Quantification of the cells shown in A with tTG at their leading edges.  (C) Serum-starved 
MDAMB231 cells were treated without (Untreated) or with myricetin, methylene blue, or 
VER 155008, and then immunofluorescence was performed on the cells using tTG and Hsp70 
antibodies..  The resulting fluorescent images are shown with the tTG and Hsp70 at leading 
edges being indicated with arrows.  (D) Quantification of the cells shown in C with tTG at 
their leading edges.  Three independent experiments were performed, with at least 250 cells 
being scored for each condition.  The results from the experiments were then averaged 
together and graphed.  The error bars indicate standard deviation.  
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Hsp70 inhibitors reduced the percentage of HeLa cells with tTG along their leading edges from 
~40% to between ~5-15%, depending on which inhibitor was used.  Hsp70 inhibition also  
blocked the leading edge accumulation of tTG in MDAMB231 breast cancer cells (Figure 2.5C), 
with the results of these experiments being quantified in Figure 2.5D, indicating that Hsp70 
activity is essential for redistributing the plasma membrane-associated pool of tTG to leading 
edges in at least two different cell types.  Moreover, it is worth emphasizing that the effect of the 
three Hsp70 inhibitors at preventing the recruitment of tTG to leading edges appears to be 
specific, and not simply a consequence of disrupting leading edge formation in cells, based on 
two additional pieces of data.  First, the characteristic build-up of actin that occurs at the leading 
edges of EGF-stimulated HeLa cells or in constitutively migrating MDAMB231 cells, that is 
necessary to promote membrane protrusions and the generation of new cell-to-substrate contacts, 
was not inhibited when the cells were exposed to either myricetin, methylene blue, or VER 
155008 (Figures 2.6A and 2.6B, respectively).  Second, we also found that myricetin treatment 
did not disrupt the ability of two ectopically expressed, activated forms of the leading edge-
resident proteins, Rac (HA-tagged Rac F28L) and Ras (HA-tagged Ras G12V), to be localized to 
these sites in MDAMB231 cells (Figure 2.6C). 
 The ATP-hydrolytic activity of heat shock proteins is essential for their ability to 
associate with client proteins (29).  While traditionally the binding of heat shock proteins to 
client proteins occurs in response to cellular stresses, such as elevated temperatures, as a means 
to help ensure proper protein folding under stressful conditions, more recently, heat shock 
proteins have been implicated in promoting human cancer progression (30,31).  Not only are the 
expression and activation levels of several heat shock proteins, including Hsp70, frequently up-
regulated in a variety of primary tumors and tumor-derived cell lines, but the ability of heat  
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 Figure 2.6  Inhibition of Hsp70 does not have a global effect on leading edge proteins. 
(A) Serum-deprived HeLa cells were treated without (Untreated) or with EGF, -/+ myricetin, 
methylene blue, or VER 155008, and then immunofluorescence was performed on the cells 
using a tTG antibody, rhodamine-conjugated phalloidin (Actin), and DAPI.  The resulting 
fluorescent images are shown with the tTG at leading edges being indicated with arrows.  (B) 
Serum-starved MDAMB231 cells were treated without (Untreated) or with myricetin, 
methylene blue, or VER 155008,  and then immunofluorescence was performed on the cells 
using a tTG antibody, rhodamine-conjugated phalloidin (Actin) and DAPI.  The resulting 
fluorescent images are shown with the tTG at leading edges being indicated with arrows.  (C) 
MDAMB231 cells were transiently transfected with either of two HA-tagged constructs: 
constitutively active Rac (F28L) or GTP hydrolysis-defective Ras (G12V), and 
immunofluorescence was performed using HA and tTG antibodies and DAPI.  The resulting 
fluorescent images are shown with the Rac, Ras, and tTG at leading edges being indicated 
with arrows.  
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shock proteins to bind to and potentiate the signaling capabilities of key mitogenic and pro-
survival signaling proteins has been shown to be necessary for inducing/maintaining the 
transformed state (30,32).  Given our novel finding that the recruitment of tTG to the leading 
edges of HeLa cells and MDAMB231 cells is dependent on Hsp70 activity, it was logical to 
consider the possibility that tTG might be a client of Hsp70.  If this were the case, then we would 
predict that the interaction between Hsp70 and tTG in cells would be sensitive to treatment with 
myricetin, methylene blue, or VER 155008, since these inhibitors function by blocking the ATP-
hydrolytic activity of Hsp70, and thereby disrupt its ability to bind client proteins through the 
conserved substrate (client) binding domain.  HeLa cells transiently co-expressing V5-tagged 
Hsc70 and Myc-tagged tTG were either left untreated or were incubated with one of the 
inhibitors and lysed.  The cell extracts were then subjected to immunoprecipitation using a Myc 
antibody, with the resulting immunocomplexes then analyzed by Western blot.  Figure 2.7A 
shows that V5-tagged Hsc70 co-immunoprecipitated with Myc-tagged tTG from each of the 
inhibitor-treated cells to a similar extent as it did from the untreated (control) HeLa cells.  This 
suggests that tTG is not a client of Hsp70 in the conventional sense and does not directly bind to 
Hsp70 through its substrate (client) binding site. 
 Next, we asked how inhibiting Hsp70 would affect tTG activity.  Serum-starved 
MDAMB231 cells that had been left untreated, or were incubated with an irreversible tTG 
crosslinking inhibitor, T101, or with myricetin, methylene blue, or VER 155008, were collected 
and then the enzymatic transamidation activities in each sample were assayed by reading-out the 
incorporation of BPA into lysate proteins.  Consistent with previous results, tTG expressed in 
serum-starved MDAMB231 cells was constitutively active, while as expected, treatment of the 
cells with the tTG inhibitor, T101, reduced tTG activity (Figure 2.7B).  However, the amount of  
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 Figure 2.7  Inhibiting the ATP-hydrolytic activity of Hsp70 has no effect on the 
interaction between tTG and Hsp70, or on the protein crosslinking activity of tTG.  (A) 
HeLa cells ectopically expressing V5-Hsc70 and Myc-tTG were treated without (Untreated) 
or with myricetin, methylene blue, or VER 155008, as indicated, and lysed.  
Immunoprecipitations with a Myc antibody were performed on the cell extracts, followed by 
SDS-PAGE and Western blot analysis using V5 and Myc antibodies.  Non-specific mouse 
IgG control antibody and beads-only control immunoprecipitations were performed on the 
extracts from the untreated cells to show that the Hsc70-tTG interaction was specific.  (B) 
Serum-starved cultures of MDAMB231 cells were treated without (Untreated) or with T101, 
myricetin, methylene blue, or VER 155008 and then lysed.  The extracts were immunoblotted 
with tTG and actin antibodies (top panels), and assayed for transamidation activity as read-out 
by the incorporation of BPA into lysate proteins (bottom panel).   
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tTG-catalyzed transamidation activity detected in the inhibitor-treated MDAMB231 cell samples 
was similar to that detected in the control sample. 
 
The recruitment of tTG to leading edges is important for cell migration 
 Our findings showing that inhibiting Hsp70 activity prevented the accumulation of tTG at 
the leading edges of cells, without affecting its transamidation activity, afforded us with a unique 
opportunity to examine the importance of tTG’s localization to leading edges on the ability of 
cells to migrate.  Multiple plates of confluent HeLa cells or MDAMB231 cells, that either were 
untreated or incubated with different combinations of EGF and myricetin, were subjected to a 
scratch (or wound healing) assay, and their rates of cell migration were compared.  The top 
panels in Figure 2.8A show that the EGF-stimulated migration of HeLa cells, as indicated by the 
ability of these cells to close the wound, was blocked when the cells were also cultured in the 
presence of myricetin.  Likewise, the constitutive migration activity normally exhibited by the 
MDAMB231 cells was also ablated by myricetin treatment (Figure 2.8A, bottom panels).  
Similar results were obtained using the two additional Hsp70 inhibitors, methylene blue (Figure 
2.8B) and VER 155008 (Figure 2.8C).  Taken together, these findings demonstrate that the 
proper localization of tTG to leading edges by Hsp70 family members is essential for the 
migration of certain human cancer cell lines.  
 
Discussion 
 Cell migration is a fundamental process in biology that underlies key stages of 
development and tissue regeneration; however, it is frequently deregulated in human diseases 
such as cancer, where the aberrant migration of cells serves as a precursor to their metastatic and  
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 Figure 2.8  Inhibition of Hsp70 blocks the migration of HeLa and MDAMB231 cells.  (A) 
Scratch assays were performed on serum-deprived HeLa cells treated without (Untreated) or 
with EGF, -/+ myricetin, and on serum-starved MDAMB231 cells -/+ myricetin.  The 
MDAMB231 cells were fixed 12 hours after striking the wound; HeLa cells were fixed after 
24 hours.  The cells were then visualized using light microscopy and the extent of wound 
closure determined.  One set of untreated cells was fixed immediately after striking the wound 
(Untreated 0 hr.) to indicate the size of the initial wounds.  The widths of the initial wounds 
are indicated by dashed lines.  (B) Scratch assays were performed on the cell lines using 
methylene blue as outlined in A.  (C) Scratch assays were performed on the cell lines using 
VER 155008 as outlined in A. 
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invasive capabilities (1,3,5,7).  For this reason, we have chosen to focus on the mechanisms used 
by cancer cells to enhance migration.  We have previously identified tTG as a non-traditional 
signaling protein that is essential for the EGF-dependent migration of HeLa cells and the 
constitutive migration of MDAMB231 cells (11).  Here we show that Hsp70 plays a critical 
regulatory role in the localization of tTG to the leading edges of actively migrating cells. 
 Given that EGF stimulation results in the accumulation of tTG at the leading edges of 
cells, our initial assumption was that a growth factor-induced trafficking event triggered the 
movement of a pool of cytosolic tTG to the plasma membrane.  However, membrane 
fractionation studies revealed that a discrete population of tTG, which comprises ~10% of the 
tTG expressed in cells, constitutively associates with the plasma membrane, and is unaffected by 
EGF treatment.  These findings supported the possibility that the membrane-associated pool of 
tTG is redistributed to leading edges following exposure to EGF.  What is particularly interesting 
is that EGF can activate this membrane-bound pool of tTG on a similar time-scale as the 
localization of tTG to leading edges.  This correlation leads us to suspect that the activation of 
the membrane-associated tTG, and its localization to the leading edge, are coupled and need to 
occur in a coordinated fashion to promote cell migration.  Support for this idea comes from 
previous studies using HeLa cells where we found that ectopically expressed tTG showed protein 
crosslinking (transamidation) activity, but its ectopic expression alone was not sufficient for 
enhancing cell migration (11).  We believe the reason for this is that the ectopically expressed 
tTG cannot localize to leading edges without EGF treatment and that such localization is 
essential for promoting cell migration. 
 Certainly an important question concerned how tTG is capable of associating with the 
plasma membrane so that it can ultimately localize to the leading edges of cells.  While tTG 
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appears to have some intrinsic capability to associate with lipid bilayers, as indicated by 
liposome experiments, sequence and structure analyses do not provide obvious clues as to how 
this might occur.  We also wondered how tTG is recruited in an EGF-dependent manner to the 
leading edge, and so we searched for interacting proteins that might help tTG to localize to these 
membrane sites.  Immunoprecipitation of tTG from membrane extracts and subsequent mass 
spectrometry analysis of the immunocomplexes led to the identification of two heat shock 
protein 70 family members, Hsp70 and Hsc70, as novel binding partners for tTG.  We further 
showed that Hsp70 and tTG co-localize to leading edges.  This suggested that Hsp70 could 
indeed play a role in the ability of tTG to accumulate at these sites.  Using several different 
inhibitors against the ATP hydrolytic activity of Hsp70, including myricetin, methylene blue, 
and VER 155008, we showed that blocking the chaperonin activity of Hsp70 prevented tTG and 
Hsp70 from co-localizing to leading edges.  Importantly, we further demonstrated that the 
exclusion of tTG and Hsp70 from leading edges caused by inhibiting Hsp70 activity was specific 
for these two proteins.  In the presence of these inhibitors, actin structures still formed at the 
leading edges of cells.  Moreover, other leading edge-resident proteins including activated forms 
of the small GTPases Rac and Ras were still able to properly localize to these membrane sites 
even when the cells were treated with myricetin, thus indicating that this inhibitor is not having a 
global effect.  Therefore, the chaperonin ability of Hsp70 appears to be critical for the 
localization of tTG to leading edges. 
 Surprisingly, treatment of cells with the Hsp70 inhibitors does not block the interaction of 
tTG and Hsp70, suggesting that tTG is not a client of Hsp70.  However, given the effect of 
myricetin, methylene blue, or VER 155008 on the localization of tTG, these findings imply that 
the interaction of Hsp70 with a certain client protein(s) is necessary for regulating the 
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localization of tTG.  It has been shown that a number of signaling proteins may be clients of heat 
shock proteins including Src, Raf, and Akt and that these chaperones may play an important role 
in extending their signaling lifetimes (30).  This then raises some interesting questions for the 
future, such as whether specific clients of Hsp70 are required to help tTG properly localize to 
leading edges. 
 Previous work by us has shown that the transamidation activity of tTG is important for 
the process of cell migration, as inhibiting this activity with MDC blocks the EGF-dependent 
migration of HeLa cells, as well as the constitutive migration of MDAMB231 cells (11).  
However, this activity is not sufficient for enhancing cell migration in either case, thereby 
suggesting that in addition to becoming activated, tTG needs to localize to leading edges.  
Initially, we used a biochemical approach to define the region of tTG that was required for its 
association with membranes in hopes of designing a tTG mutant that retained protein 
crosslinking activity, but was defective for binding to the plasma membrane.  Thus far, we have 
not been able to identify a point mutant that uncouples these two functions of tTG.  However, 
our identification of Hsp70 as a novel binding partner of tTG, and the fact that these two proteins 
co-localize to leading edges with the localization being blocked by myricetin, as well as 
methylene blue and VER 155008, provided us with a nice system for specifically investigating 
the importance of the leading edge-localization of tTG.  In particular, because these Hsp70 
inhibitors do not affect the protein crosslinking activity of tTG, it is possible to uncouple this 
function from its leading edge localization and determine what effect this has on cell migration.  
Indeed, we have shown that by blocking either tTG protein crosslinking activity (using MDC), or 
its leading edge-localization (using myricetin, methylene blue, or VER 155008), we are able to 
inhibit cell migration, demonstrating that these two events are coupled. 
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 These findings now raise a number of intriguing questions regarding the role of heat 
shock proteins in cancer progression.  Recently, it was shown that Hsp70 and Hsc70 are uniquely 
capable of interacting with lipids, as they can insert into artificial lipid bilayers and selectively 
bind to phosphatidylserine (28).  Others have demonstrated that Hsp70 can bind to cholesterol-
rich microdomains in tumor cells (27).  Still, the importance of the membrane association of 
Hsp70 and the consequences this holds for cancer progression, are not yet understood.  Here we 
offer a possible insight into why these chaperones localize to the plasma membrane, namely, to 
regulate a key signaling molecule, tTG, and facilitate its redistribution to leading edges.  We 
believe that the identification of Hsp70’s client proteins will provide additional insights into the 
roles of Hsp70 and tTG in cell migration.  All of this then leads to the question of why tTG needs 
to localize to leading edges.  We believe that the coupling of tTG localization with the activation 
of its protein crosslinking activity should shed light on the identity of a key transamidation 
substrate for tTG.  The recent development of “clickable” inhibitors against tTG, which bind to 
only the transamidation-active form of the enzyme, offer the possibility of visualizing tTG-
catalyzed protein crosslinking activity in cells (33).  These inhibitors may prove very useful for 
determining whether tTG is active specifically at leading edges.  If this is the case, we will want 
to identify the substrate(s) of tTG located at these leading edges and determine how crosslinking 
contributes to enhanced cell migration. 
 
Materials and Methods 
Materials.  All cell culture reagents, the Colloidal Blue staining kit, EGF, Lipofectamine, 
Lipofectamine 2000, protein G-beads, and V5 antibody, as well as the control, tTG, and Hsp70 
siRNAs were from Invitrogen.  Monodansylcadaverine (MDC), 6-diamidino-2-phenylindole 
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(DAPI), myricetin, methylene blue, and the fibronectin antibody were obtained from Sigma, 
while VER 155008 was from Tocris Biosciences.  The tTG and actin antibodies were from 
Neomarkers, the IκBα, Hsp70, and cortactin antibodies were from Cell Signaling, and the HA 
and Myc antibodies were from Covance.  The biotinylated pentylamine (BPA) was from Pierce, 
and T101 was from Zedira.  The Quick Blue staining kit was from Boston Biologicals. 
 
Cell culture.  HeLa and MDAMB231 cells were grown in RPMI 1640 medium containing 10% 
fetal bovine serum (FBS).  The pcDNA3 constructs encoding V5-tagged Hsc70, the various 
forms of Myc-tagged tTG, and the HA-tagged forms of activated Rac and Ras, were transfected 
into cells using Lipofectamine, whereas the control, tTG, and Hsp70 siRNAs were introduced 
into cells using Lipofectamine 2000.  As indicated, cell cultures or cell extracts were treated with 
various combinations of 0.1 µg/mL EGF, 50 µM myricetin, 10 μM methylene blue, 50 μM VER 
155008, and 1.0 µM T101.  The cells were then either collected for cell fractionation, fixed with 
3.7% formaldehyde, or lysed with cell lysis buffer (25 mM Tris, 100 mM NaCl, 1% Triton X-
100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM β-glycerol phosphate, 1 μg/mL aprotinin, 
and 1 μg/mL leupeptin).  The Bio-Rad DC protein assay was used to determine protein 
concentrations.  
 
Immunofluorescence.  The fixed cells were permeabilized with PBS containing 0.1% Triton X-
100, blocked in PBS containing 10% bovine serum albumin (BSA), and incubated with the 
indicated primary antibodies for 2 hours.  The cells were then incubated with either Oregon 
green 488- or Rhodamine red-conjugated secondary antibody (Molecular Probes) for 1 hour.  
Where indicated, Rhodamine-conjugated phalloidin was used to stain actin filaments, while 
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DAPI was used to stain nuclei.  Following the secondary incubations, the cells were washed 
extensively with PBS, mounted, and visualized using the 63X objective on a Zeiss Axioskop 
fluorescent microscope.  Images were captured and processed using IPLAB. 
 
Cell migration (scratch) assays.  Parental cells or cells expressing the control siRNA or tTG 
siRNAs were grown to confluence and then put in serum-free medium without or with 0.1 
µg/mL EGF, and without or with 20 µM MDC, as indicated.  Fifteen hours later, a wound was 
struck using a pipet tip and the culturing medium on the cells was replenished to remove 
detached cells.  When examining the effects of myricetin, methylene blue, and VER 155008 on 
cell migration, cells maintained in serum-free medium for 15 hours, -/+ 0.1 μg/mL EGF, were 
treated without or with one of the inhibitors for one hour before striking a wound and 
replenishing the medium.  After the indicated incubation period, the cells were fixed and 
visualized by light microscopy.  Each of these experiments was performed at least 3 times.  
 
Cell fractionation.  To fractionate cells into their cytosolic and membrane components, harvested 
cells were re-suspended in homogenization buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 200 
mM sucrose, and 1 mM PMSF) and homogenized using a dounce homogenizer.  The cell 
extracts were then centrifuged at 1,000 rpm for 10 minutes to remove the intact nuclei, followed 
by centrifugation at 47,000 rpm for 1.5 hours to pellet cellular membranes.  The soluble cytosolic 
fraction was removed and saved, while the membrane fraction was lysed in membrane lysis 
buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM PMSF, and 0.5% Triton X-100) for 1 
hour, followed by centrifugation at 13,000 rpm for 10 minutes to remove any insoluble material.  
 
95
Transamidation assays.  Cell lysates (15 μg of each) were incubated in a buffer containing 10 
mM dithiothreitol, 10 mM CaCl2, and 50 μM BPA for 10 minutes.  The reactions were stopped 
with the addition of Laemmeli sample buffer, followed by boiling, and the proteins were 
resolved on a gel, transferred to polyvinylidene fluoride (PDVF) membranes, and blocked for at 
least 1 day in BBST (100 mM boric acid, 20 mM sodium borate, 0.01% SDS, 0.01% Tween 20, 
and 80 mM NaCl) containing 10% BSA.  The membranes were incubated with horseradish-
peroxidase-conjugated streptavidin, diluted at 1:2000 in BBST containing 5% BSA for 1 hour, 
and then washed extensively with BBST.  The proteins that incorporated BPA were visualized 
on X-ray film after exposing the membranes to ECL reagent.   
 
In vitro liposome fractionation assays.  Synthetic liposomes were prepared from a lipid mixture 
containing 35% phosphatidylethanolamine, 25% phosphatidylserine, 5% phosphatidylinositol, 
and 35% cholesterol re-suspended in TBSM buffer (20 mM Tris, pH 7.5, 150 mM NaCl, and 2 
mM MgCl2).  The lipids were extruded through an 8 micron filter, pelleted by centrifugation at 
13,000 rpm for 15 minutes, and re-suspended in TBSM buffer.  Equal amounts of the lipid 
preparation were then incubated with either recombinant wild-type tTG or BSA for 15 minutes, 
followed by centrifugation at 13,000 rpm for 10 minutes at room temperature.  The supernatant 
was concentrated to ~30 µL using a microfuge concentrator with a 10K molecular weight cut-
off, while the pelleted liposomes were re-suspended in 30 µL of TBSM buffer.  Each of the 
samples was resolved on a gel and then stained with Quick Blue to detect proteins. 
 
Immunoprecipitations.  Cell lysates (~1.2 mg) that had been pre-cleared with protein G-beads 
were incubated with nothing, a Myc antibody or a non-specific mouse IgG control antibody for 
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1.5 hours as indicated.  Protein G-beads were then added to the lysates and incubated for an 
additional 1.5 hours, at which time the beads were washed extensively with cell lysis buffer. 
 
Immunoblot analysis.  Whole cell extracts, various isolated subcellular fractions, as well as 
immunoprecipitated proteins were resolved by SDS-PAGE, followed by transfer to PVDF 
membranes.  The membranes were incubated with the indicated primary antibodies diluted in 
TBST (in 20 mM Tris, 135 mM NaCl, and 0.02% Tween 20).  The primary antibodies were 
detected with horseradish-peroxidase-conjugated secondary antibodies followed by exposure to 
ECL reagent.  Some of the resulting blots were quantified using Image-J software.  
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CHAPTER 3 
 
Tissue Transglutaminase Promotes Cell Survival Through a Mechanism Involving c-Src 
and PI3-kinase
*
 
 
Introduction 
 Tissue transglutaminase (tTG) functions as a GTPase and an acyl transferase that 
catalyzes the formation of protein crosslinks.  tTG expression and activation are frequently up-
regulated in human cancer, where it has been implicated in a number of aspects of cancer cell 
growth and metastasis, including cell survival and chemo-resistance.  However, the extent to 
which tTG cooperates with oncogenic proteins within the context of a cancer cell, versus its 
intrinsic ability to confer transformed characteristics to cells, is poorly understood.  To address 
this question, we asked what effect the ectopic expression of tTG in a normal (non-transformed) 
cellular background would have on the behavior of the cells.  Using NIH3T3 fibroblasts stably 
expressing a Myc-tagged form of tTG, we found that tTG strongly protected these cells from 
serum-starvation-induced apoptosis and triggered the activation of the PI3-kinase/mTOR/p70 
S6-kinase pathway.  We determined that tTG forms a complex with the non-receptor tyrosine 
kinase c-Src and PI3-kinase, and that treating cells with inhibitors to block tTG function 
(monodansylcadaverine; MDC) or c-Src kinase activity (PP2) disrupted the formation of this 
complex, and prevented tTG from activating the PI3-kinase pathway.  Moreover, treatment of 
fibroblasts over-expressing tTG with PP2, or with inhibitors that inactivate components of the 
PI3-kinase pathway, including PI3-kinase (LY294002) and mTOR (rapamycin), ablated the tTG-
                                                          
*
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promoted survival of the cells.  These findings demonstrate that tTG has an intrinsic capability to 
stimulate cell survival through a novel mechanism that activates PI3-kinase signaling events, 
thus highlighting tTG as a potential target for the treatment of human cancer. 
 Tissue transglutaminase (tTG) is a protein that is capable of multiple catalytic activities.  
In particular, tTG can bind and hydrolyze GTP like members of the large and small families of 
GTPases (i.e. Rho, Rac, Cdc42, and Ras) (1-3).  It also exhibits a calcium-dependent acyl 
transferase activity (transamidation) that catalyzes the formation of an amide bond between the 
γ-carboximide group of a glutamine residue within one protein and the primary amino groups or 
the ε-amino group of a lysine residue within another protein (4,5).  The generation of these 
protein-protein crosslinks by tTG has been implicated in the regulation of a wide array of cellular 
processes, ranging from the maintenance of the extracellular matrix and cell adhesion to the 
induction of cellular differentiation and apoptosis (6-10).  However, tTG has also been suggested 
to play crucial roles in the progression of a number of human disease states.  In particular, during 
the past decade, several laboratories, including our own, have shown that increases in tTG 
expression and/or its enzymatic transamidation activity are hallmarks of various types of human 
cancer including breast, brain, ovarian, and pancreatic cancer (11-16).  In many of these same 
studies, it was also shown that knocking-down tTG expression by RNAi in cancer cell lines 
where it was aberrantly expressed, or interfering with its ability to crosslink proteins by treating 
the cells with inhibitors like MDC, either ablated the growth of the cancer cells or made them 
more sensitive to chemotherapy and other types of apoptotic-inducing cellular stress (11-13,16). 
 The indications that the over-expression of tTG contributes to tumor progression and 
metastasis raise an important question, namely to what extent are the contributions of tTG to 
cancer progression shaped by the cancer cell context and the various oncogenic signaling 
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proteins present within transformed cells, versus the intrinsic ability of tTG to alter normal 
cellular behavior.  Indeed, various studies have suggested that tTG can work together with 
oncogenic signaling proteins in the background of a cancer cell (17-20).  One example from 
studies performed in our laboratory involves the ability of tTG to influence the transformed 
characteristics of human breast cancer cells.  In particular, we discovered, when using the human 
SKBR3 breast cancer cell line as a model, that tTG expression and activation were strongly up-
regulated in an epidermal growth factor (EGF)-dependent manner.  Moreover, tTG was essential 
for the EGF-stimulated growth of these cancer cells in monolayer, as well as for their anchorage-
independent growth and importantly, their survival in the face of stress conditions and apoptotic 
challenges such as chemotherapeutic agents (20).  We then demonstrated that a key element in 
the transformed characteristics of these breast cancer cells, as imparted by tTG, was its ability to 
form a complex with the non-receptor tyrosine kinase and proto-oncogene c-Src. 
 Here, we have set out to determine whether tTG has the ability to alter the behavior of 
normal (non-transformed) cells, as a means of obtaining insights into the capability of this 
protein in the absence of a cancer cell context to induce characteristics necessary for malignant 
transformation.  To address this important question, we have examined the biological 
consequences of ectopically expressing tTG in NIH3T3 cells, a normal fibroblast cell line.  
Interestingly, we found that tTG strongly promoted NIH3T3 cell survival by enhancing the 
activation of the canonical PI3-kinase/mTOR/p70 S6-kinase pathway.  We then went on to 
demonstrate that the ability of tTG to activate this signaling pathway was through the assembly 
of a complex consisting of tTG, c-Src, and PI3-kinase.  Importantly, treating the cells with either 
the Src inhibitor, PP2, or the tTG inhibitor, MDC, disrupted the interaction between c-Src and 
tTG, as well as blocked the ability of tTG to stimulate PI3-kinase-mediated signaling events.  
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Thus, these findings point to tTG as being a key participant in a c-Src-PI3-kinase signaling 
pathway and that it is able to assemble this signaling complex even in a non-transformed cellular 
context.  This capability is likely to have important consequences for enabling cancer cells to 
survive various apoptotic challenges including treatment with chemotherapeutic drugs.  
 
Results 
Ectopic expression of tTG in fibroblasts promotes cell survival 
 Increases in tTG expression and activation occur in several different types of human 
cancer resulting in a wide range of potential interactions and cross-talk with oncogenic proteins 
that drive transformation (12,14,20-22).  This has contributed to some confusion in the field 
regarding the many possible roles that tTG plays in cancer progression.  In particular, it has been 
extremely difficult to identify the inherent and fundamental actions of tTG that contribute to the 
development of the malignant state.  In order to determine the intrinsic capability of tTG to 
mediate actions relevant to cancer progression, we examined the effects of over-expressing this 
protein in a normal (non-transformed) cell type.  The NIH3T3 mouse fibroblast cell line was 
chosen as our model system for this study, as it is commonly used to read-out various types of 
cellular outcomes (23-25).  Consistent with earlier findings, Figure 3.1A (top panel, first lane) 
shows that these cells fail to express detectable levels of tTG.  We then generated two different 
NIH3T3 stable cell lines; one expressing the vector alone and the other expressing a Myc-tagged 
form of wild-type tTG (Figure 3.1A, second panel from the top, second and third lanes).  The 
tTG ectopically expressed in the fibroblasts is functionally active, as indicated by its ability to 
catalyze the incorporation of biotinylated pentylamine (BPA) into lysate proteins, as compared to  
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 Figure 3.1  Ectopic expression of tTG in NIH3T3 fibroblasts promotes cell growth and 
survival.  (A) Whole cell lysates of parental NIH3T3 cells, or NIH3T3 cells stably expressing 
the vector alone or a Myc-tagged form of tTG, were immunoblotted with tTG, Myc, and actin 
antibodies.  The same cell lysates were also assayed for transamidation (crosslinking) activity 
by determining the incorporation of BPA into lysate proteins as described in “Experimental 
Procedures”.  (B) Focus formation assays were carried-out on parental fibroblasts that were 
transiently transfected without (Mock), or with expression plasmids encoding either Myc-
tagged tTG (tTG), or an HA-tagged activated form of Ras (H-Ras G12V).  The cells were 
maintained in DMEM supplemented with 10% CS for 10 days, at which time they were fixed 
and stained with crystal violet.  Shown are representative images of the resulting foci that 
formed for each condition.  (C) Cell migration (scratch) assays were performed on NIH3T3 
cells stably expressing the vector alone or a Myc-tagged form of tTG.  Twenty-four hours 
after striking the wound, the cells were fixed and then visualized by light microscopy to 
determine the extent of wound closure.  One set of vector alone-expressing fibroblasts was 
fixed immediately after striking the wound (Control 0 hr.) to indicate the width of the initial 
wound (indicated by dashed lines).  (D) Cultures of the NIH3T3 cells stably expressing the 
vector alone or a Myc-tagged form of tTG were placed in serum-free medium for 36 hours, at 
which time they were collected and stained with DAPI to identify condensed and/or blebbed 
nuclei.  Percent apoptosis was determined by calculating the ratio of apoptotic to non-
apoptotic cells.  The experiments were performed in triplicate and the results were averaged.  
The error bars indicate standard deviation.  (E) Growth in low serum assays were performed 
on NIH3T3 cells stably expressing the vector alone or Myc-tagged tTG by plating them at a 
density of 2x10
4
 cells/dish in 6-well dishes and then placing them in DMEM containing 0.1% 
CS.  Every other day for 6 days, one set of cells was counted, while on the remaining sets of 
cells the medium was replenished.  The experiments were performed in triplicate and the 
results were averaged together and graphed.  The error bars indicate standard deviation. 
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parental or vector alone-expressing fibroblasts, which have little if any detectable crosslinking 
activity (Figure 3.1A, bottom panel).   
 Previous work from our laboratory had suggested that over-expressing tTG in normal cell 
lines was not sufficient to induce transformation, as indicated by their inability to exhibit 
anchorage-independent growth (i.e. as assayed by colony formation in soft agar) (26).  Here, we 
followed-up on these findings by performing focus formation assays on NIH3T3 cells ectopically 
expressing tTG.  The ability of cells to form foci (i.e. distinct areas of high cell density) 
represents another indicator of cellular transformation that measures the ability of cells to 
overcome the contact inhibition exhibited by non-transformed cells when grown in monolayer.  
For these experiments, cultures of parental fibroblasts were transiently transfected without 
(Mock), or with expression plasmids encoding either tTG (tTG) or an oncogenic form of Ras (H-
Ras G12V), and then were maintained in normal growth medium (DMEM containing 10% CS) 
for 10 days.  The resulting cell cultures were then fixed and stained with crystal violet to 
highlight any differences in cell densities (i.e. foci) that might have occurred as an outcome of 
expressing tTG or activated H-Ras in the cells.  As anticipated, fibroblasts expressing oncogenic 
Ras (H-Ras G12V) formed numerous foci (Figure 3.1B, bottom panel), while neither the control 
fibroblasts (Mock) (Figure 3.1B, top panel), nor the NIH3T3 cells transiently transfected with the 
tTG plasmid (Figure 3.1B, middle panel), showed detectable foci.  
 Given that tTG has been shown to localize to the leading edges of actively migrating 
cancer cells where it promotes the EGF-stimulated migration of the HeLa cervical carcinoma cell 
line, as well as the constitutive migration exhibited by the MDAMB231 breast cancer cell line 
(17,27), we next examined whether the over-expression of tTG in NIH3T3 cells would enhance 
their ability to migrate.  The NIH3T3 cells stably expressing the vector alone or a Myc-tagged  
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form of tTG were subjected to wound healing (scratch) assays to determine whether there was 
any difference in the rate at which these cell lines migrated.  Figure 3.1C shows that the extent of 
cell migration into the wound by fibroblasts expressing the vector alone, versus Myc-tagged tTG, 
was similar, suggesting that tTG is not important for promoting the general migration of these 
cells. 
 We then examined the ability of tTG to impact cell survival.  Serum starvation is a stress 
that induces a cell death response in a number of cell types, including NIH3T3 fibroblasts 
(26,28).  Thus, we took cultures of NIH3T3 cells stably expressing the vector alone or Myc-
tagged tTG and placed them in serum-free medium for ~36 hours.  The cells were then collected 
and the extent of cell death was determined by staining the cells with DAPI and examining them 
for the appearance of condensed and/or blebbed nuclei, an indicator of apoptosis.  Figure 3.1D 
shows that ~70% of vector alone-expressing cells were apoptotic when cultured in medium 
lacking serum.  In contrast, ~30% of the tTG-expressing fibroblasts were apoptotic under the 
same culturing conditions, suggesting tTG strongly promotes the survival of the fibroblasts.  
Similarly, the growth rates of the stable cell lines maintained in medium containing 0.1% serum 
(low serum conditions) over the course of 6 days were also assessed.  The results in Figure 3.1E 
show that tTG promoted the growth of fibroblasts cultured under low serum conditions, as 
evidenced by the continued growth of the cells stably expressing tTG, whereas, the growth rate 
of the cells expressing the vector alone was stunted.  This data suggests that tTG expression in a 
normal non-transformed cell type is sufficient to promote some aspects of cellular 
transformation, in particular, cell survival and growth in low serum. 
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tTG activates PI3-kinase 
 To further explore how tTG promotes cell survival, the NIH3T3 stable cell lines were 
maintained in serum-free medium for 24 hours and lysed.  The whole cell lysates were then 
subjected to Western blot analysis using antibodies which detect the activated or phosphorylated 
forms of several traditional signaling proteins known to promote cell survival, with the 
expectation being that if tTG promotes cell viability by activating certain signaling proteins, then 
we should be able to detect an increase in the activation of these proteins in the fibroblasts 
expressing Myc-tagged tTG compared to the cells expressing the vector alone.  The proteins 
whose activities were examined included members of the mitogen activated protein (MAP) 
kinase family, specifically, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal 
kinase (JNK), as well as components of the canonical PI3-kinase signaling cascade, namely, 
AKT, mammalian target of rapamycin (mTOR), and p70 S6-kinase (p70S6K).  Figure 3.2A 
shows that when using antibodies recognizing the activated form of ERK, as well as the 
phosphorylation of the transcription factor c-Jun at Ser63 and Ser73 (i.e. two known JNK 
phosphorylation sites), we found that neither of these MAP kinase family members were 
activated by tTG over-expression (third and fourth panels from the top, respectively).  However, 
components of the PI3-kinase pathway were significantly affected.  Specifically, fibroblasts 
ectopically expressing tTG showed higher levels of AKT (fifth and sixth panels from the top), 
mTOR (eighth panel from the top), and p70 S6-kinase activity (tenth panel from the top) 
compared to control cells, while the overall expression levels of each of these signaling proteins 
remained constant (seventh, ninth, and eleventh panels from the top, respectively).  
 To further confirm that these results were due to the ectopic expression of tTG, we 
treated the stable cell lines without or with the tTG inhibitor, MDC, which competes with  
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 Figure 3.2  tTG promotes activation of the PI3-kinase/mTOR/p70 S6-kinase pathway.  
(A) NIH3T3 cells stably expressing the vector alone or a Myc-tagged form of tTG were 
placed in serum-free medium for 24 hours, at which time they were lysed and subjected to 
Western blot analysis using the indicated antibodies. (B) The same stable cell lines were 
cultured in serum-free medium supplemented without (0) or with MDC for 24 hours at which 
time they were lysed.  The whole cell lysates were then subjected to Western blot analysis 
using the indicated antibodies. 
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substrates for binding to the transamidation active site.  Figure 3.2B shows that MDC treatment 
blocked the increases in AKT, mTOR, and p70 S6-kinase activities observed in fibroblasts over-
expressing tTG (third, fourth, sixth, and eighth panels from the top, respectively), again without  
altering the expression levels of each of these proteins (fifth, seventh, and ninth panels from the 
top, respectively).  
 
The ability of tTG to activate the PI3-kinase pathway requires Src kinase activity 
 We wanted to learn more about how the over-expression of tTG in NIH3T3 cells leads to 
increased activation of PI3-kinase and several of its downstream effectors, namely AKT, mTOR, 
and p70 S6-kinase.  Based on a recent suggestion that tTG can down-regulate the expression of 
the lipid phosphatase and major negative regulator of PI3-kinase signaling, PTEN (for 
phosphatase and tensin homologue deleted on chromosome ten), in pancreatic cancer cells (22), 
we first examined whether tTG was similarly affecting PTEN expression to promote PI3-kinase 
signaling activity in NIH3T3 cells.  However, this was ruled out when we compared the levels of 
PTEN in the lysates collected from the NIH3T3 fibroblasts expressing the vector alone to those 
expressing Myc-tagged tTG and found that they were similar (Figure 3.2A, bottom panel).  
Moreover, we also determined whether the phosphorylation of PTEN was increased in the 
fibroblasts over-expressing tTG, as the phosphorylation of PTEN in its C-terminal tail has been 
shown to inhibit its phosphatase activity, as well as enhance its stability (29,30).  However, the 
relative amounts of phosphorylated PTEN detected in these same whole cell lysates were nearly 
identical (Figure 3.2A, second panel from the bottom), further confirming that tTG is not 
stimulating the PI3-kinase pathway by inhibiting PTEN.  
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 The non-receptor tyrosine kinase c-Src, as well as other members of the Src family, can 
bind and phosphorylate the p85 regulatory subunit of PI3-kinase (31-33).  This phosphorylation 
event is believed to induce a conformational change in p85 that allows the p110 catalytic subunit 
of PI3-kinase to become activated and signal to its downstream effectors (i.e. AKT, mTOR, and 
p70 S6-kinase) (34,35).  Moreover, it has been shown that the ability of c-Src to stimulate PI3-
kinase activity is critical for Src-mediated cellular transformation, highlighting that these two 
proteins can participate in a common signaling pathway important for malignant transformation 
(36,37).   Interestingly, our laboratory recently reported that tTG can bind and activate c-Src in 
human SKBR3 breast cancer cells stimulated with EGF (20).  Since c-Src interacts with both 
PI3-kinase and tTG, and the over-expression of tTG in fibroblasts enhances the activation of the 
PI3-kinase pathway, we asked whether Src activity was important for the ability of tTG to 
stimulate PI3-kinase/mTOR/p70 S6-kinase signaling.  To address this question, serum-starved 
fibroblasts stably expressing the vector alone or Myc-tagged tTG were incubated without or with 
the Src kinase inhibitor PP2, before being lysed and then immunoblotted to read-out the effects 
of this treatment on p70 S6-kinase activity.  Figure 3.3A shows that inhibiting Src in cells 
expressing Myc-tagged tTG reduced the levels of p70 S6-kinase activity (third panel from the 
top) to those observed in control cells expressing the vector alone.  Thus, c-Src kinase activity is 
indeed necessary for tTG to activate the PI3-kinase pathway.  
 This finding prompted us to then determine whether the activation of c-Src was sufficient 
to mimic the effects of tTG and stimulate PI3-kinase-mediated signaling events.  NIH3T3 cells 
stably expressing the vector alone or a Myc-tagged form of tTG were transiently transfected 
without (Mock) or with an HA-tagged mutant form of Src that lacks a critical C-terminal 
inhibitory phosphorylation site, making it constitutively active (HA-v-Src) (38).  The  
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 Figure 3.3  Src activity is required for tTG-stimulated PI3-kinase activation.  (A) 
NIH3T3 cells stably expressing the vector alone or Myc-tagged tTG were placed in serum-
free medium for 12 hours, at which time they were treated without (0) or with PP2 for an 
additional 12 hours.  The cells were then lysed and the cell extracts were subjected to Western 
blot analysis using the indicated antibodies.  (B) The stable cell lines were transfected without 
(Mock) or with an HA-tagged constitutively active form of Src (v-Src) and then were 
maintained in serum-free medium for 12 hours.  The cells were lysed and the extracts 
subjected to Western blot analysis using the indicated antibodies. 
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transfectants were maintained in serum-free medium for 12 hours, before being lysed and 
subjected to Western blot analysis.  Using p70 S6-kinase activation as the read-out for activation 
of the PI3-kinase pathway, we found that despite the relatively high expression of HA-tagged v-
Src in the vector alone-expressing cells (Figure 3.3B, second panel from the top), only a modest  
increase in p70 S6-kinase activity (fourth panel from the top) was detected, that was significantly 
less than the activity observed in fibroblasts over-expressing tTG.  It is also worth noting that the 
ectopic expression of HA-tagged v-Src in cells stably expressing tTG did not enhance p70 S6-
kinase activity beyond that observed in cells stably expressing tTG alone.  Taken together, these 
results suggest that while c-Src kinase activity is necessary for tTG to activate PI3-kinase, it is 
not sufficient to completely mimic the effects of tTG. 
 
tTG forms a complex with Src and PI3-kinase 
 How then does tTG cooperate with c-Src to activate the PI3-kinase pathway?  Since Src 
was previously shown to bind and phosphorylate the p85 regulatory subunit of PI3-kinase, which 
induces the activation of its p110 catalytic subunit, we examined the possibility that tTG 
stimulates PI3-kinase activity by enhancing the ability of Src to interact with and phosphorylate 
p85.  Whole cell lysates generated from HEK293T cells that had been transiently transfected 
with a Myc-tagged tTG construct, alone, or together with an HA-tagged c-Src construct (Figure 
3.4A, left panels) were subjected to immunoprecipitations using an HA antibody.  Figure 3.4A 
(right panels) shows that, indeed, tTG co-immunoprecipitates with c-Src, similar to what our 
laboratory has shown in the past (20).  Surprisingly, we also found that tTG is capable of 
interacting with PI3-kinase.  For these experiments, rather than transiently expressing Myc-
tagged tTG together with HA-tagged c-Src, we instead co-expressed Myc-tagged tTG together  
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 Figure 3.4  tTG binds Src and PI3-kinase.  (A) Immunoprecipitations were performed 
using an HA antibody on whole cell lysates collected from HEK293T cells ectopically 
expressing Myc-tagged tTG, or Myc-tagged tTG and HA-tagged c-Src.  A beads only control 
was included to confirm the specificity of the interaction.  The whole cell lysates (WCL) and 
the resulting immunocomplexes (IP:HA-c-Src) were blotted with Myc and HA antibodies.  
(B) Immunoprecipitations were performed using an HA antibody on extracts collected from 
HEK293T cells ectopically expressing Myc-tagged tTG, or Myc-tagged tTG together with 
either the HA-tagged form of the p110 catalytic subunit of PI3-kinase (HA-p110) or the p85 
regulatory subunit of PI3-kinase (HA-p85).  A beads only control was included to confirm the 
specificity of the interactions.  The whole cell lysates (WCL) and the resulting 
immunocomplexes (IP:HA-tagged p110 or p85) were blotted with Myc and HA antibodies.  
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with one of the two subunits of PI3-kinase; the p110 catalytic subunit (HA-tagged p110) or the 
p85 regulatory subunit (HA-tagged p85).  Figure 3.4B (left panels) shows that the ectopic 
expression of these constructs in cells was similar.  Immunoprecipitations using an HA antibody  
performed on the whole cell lysates prepared from these transfectants showed that tTG co-
immunoprecipitates with both of the PI3-kinase subunits (Figure 3.4B, right panels). 
 Is the formation of a complex between tTG, Src, and PI3-kinase responsible for the 
enhanced PI3-kinase signaling observed in the tTG-expressing fibroblasts?  Given that the tTG 
inhibitor MDC and the Src inhibitor PP2 can abrogate the enhanced PI3-kinase signaling 
observed in fibroblasts stably expressing tTG, we reasoned that if the formation of a trimeric 
complex was important for this outcome, MDC and PP2 might then inhibit its formation.  To test 
this, tTG was expressed alone, or together with c-Src or p85, in HEK293T cells and then the 
cells were treated without or with either PP2 or MDC for 6 hours prior to being lysed.  The cell 
extracts were then incubated with an HA antibody to immunoprecipitate either the HA-tagged 
forms of c-Src or p85 expressed in the cell lysates (Figure 3.5A, second and third panels from 
the top, respectively).  The resulting immunocomplexes were also immunoblotted with a Myc 
antibody to detect the extent that tTG interacted with c-Src or p85 under conditions where Src or 
tTG activity was inhibited.  Figure 3.5A (top panel) shows that the interaction between tTG and 
p85 was insensitive to treatment with either PP2 or MDC, suggesting that the ability of these to 
proteins to interact with one another does not require c-Src kinase activity, nor access to the 
transamidation active site of tTG.  On the other hand, PP2 and MDC blocked the ability of tTG 
to co-immunoprecipitate with Src, suggesting that the activity of both of these proteins promotes 
the ability of Src to interact with tTG. 
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 Figure 3.5  Inhibiting tTG or Src activity blocks the ability of tTG to bind Src and the 
ability of Src to phosphorylate p85.  (A) HEK293T cells ectopically expressing Myc-tagged 
tTG (tTG), Myc-tagged tTG and HA-tagged c-Src (tTG/c-Src), or Myc-tagged tTG and the 
HA-tagged p85 regulatory subunit of PI3-kinase (tTG/p85), were treated without (0) or with 
PP2 or MDC for 6 hours and then lysed.  The cell lysates were subjected to 
immunoprecipitations using an HA antibody.  A beads only control was included to confirm 
the specificity of the interactions.  The whole cell lysates (WCL) and the resulting 
immunocomplexes (IP:HA-tagged c-Src or p85) were blotted using Myc and HA antibodies.  
(B) HEK293T cells co-expressing Myc-tagged tTG and HA-tagged p85 (tTG/p85) were 
treated without (0) or with PP2 or MDC for 6 hours and then lysed.  The lysates were 
subjected to immunoprecipitations using an HA antibody.  The whole cell lysates (WCL) were 
blotted with Myc and HA antibodies.  The resulting immunocomplexes (IP:HA-p85) were 
first blotted with a phosphotyrosine antibody.  The blot was then stripped and re-probed with 
an HA antibody to confirm that an equal amount of p85 was immunoprecipitated for each 
condition.  (C) The experiment shown in “B” was performed in triplicate and the extent of 
HA-tagged p85 tyrosine phosphorylation detected by Western blot analysis was quantified for 
each condition and averaged and graphed.  The error bars represent standard deviation. 
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Src has been shown to phosphorylate p85 and to stimulate the signaling capability of PI3-kinase 
(31).  This, coupled with the fact that we find tTG is able to form a complex with both PI3-
kinase and c-Src, raised the interesting possibility that tTG functions as a scaffold to more 
efficiently bring Src and PI3-kinase together.  To test this, Myc-tagged tTG was transiently  
expressed along with HA-tagged p85 in HEK293T cells, and then the cells were incubated 
without or with PP2 or MDC.  The cells were lysed and the HA-tagged p85 was 
immunoprecipitated from the extracts using an HA antibody.  The resulting immunocomplexes 
were first immunoblotted with a phosphotyrosine antibody to detect whether p85 was 
phosphorylated.  Figure 3.5B (top panel) shows that p85 is indeed phosphorylated in the control 
lysates (0), whereas the tyrosine phosphorylation is decreased by ~80% with PP2 treatment and 
~60% with MDC.  The blot was then stripped and re-probed with HA antibody to confirm that an 
equivalent amount of p85 was immunoprecipitated for each condition (Figure 3.5B, second panel 
from the top).  These experiments were performed multiple times and the results from each 
experiment were quantified and graphed (Figure 3.5C).  
 
Inhibiting Src and components of the PI3-kinase pathway eliminate tTG-enhanced cell survival 
 The over-expression of tTG in NIH3T3 cells protects them from serum-starvation-
induced apoptosis, as well as increases the activities of AKT, mTOR, and p70 S6-kinase, leading 
us to propose that tTG-promoted cell survival is dependent on its ability to activate the PI3-
kinase pathway.  Thus, we examined whether treating serum-starved fibroblasts expressing tTG 
with inhibitors of different components of this pathway, including PP2 (to inhibit Src activity), 
LY294002 (to inhibit PI3-kinase activity), and rapamycin (to inhibit mTOR activity), blocked 
the protective effect of tTG and re-sensitized the cells to serum-starvation-induced apoptosis.   
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 Figure 3.6  Inhibition of Src, PI3-kinase, or mTOR blocks the tTG-enhanced cell 
survival.  (A and B)  NIH3T3 cells stably expressing the vector alone or Myc-tagged tTG 
were placed in serum-free medium supplemented without or with PP2, LY294002, or 
rapamycin for 36 hours, at which time the cells were collected and stained with DAPI to 
identify condensed and/or blebbed nuceli.  Percent apoptosis was determined by calculating 
the ratio of apoptotic to non-apoptotic cells.  The experiments were performed in triplicate 
and the results were averaged.  The error bars indicate standard deviation.  
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Figure 3.6A shows again that tTG over-expression strongly prevented the cells deprived of 
serum from undergoing cell death.  However, the protective effect of tTG was completely 
ablated when the cells were treated with PP2.  Likewise, LY294002 and rapamycin treatment 
blocked the ability of tTG to promote cell survival (Figure 3.6B), suggesting that tTG-promoted  
survival depends on its ability to activate the PI3-kinase signaling pathway.  This led us to 
propose the model shown in Figure 3.7, where tTG, functioning as a scaffold, brings c-Src and 
PI3-kinase in proximity to one another.  Src is then able to phosphorylate the p85 regulatory 
subunit of PI3-kinase, leading to the activation of the p110 catalytic subunit and its downstream 
effectors, AKT, mTOR, and p70 S6-kinase, which ultimately results in enhanced cell survival.  
 
Discussion 
 There have been an increasing number of studies implicating tTG in cancer progression.  
tTG expression is frequently up-regulated in a number of types of human cancer, particularly 
those that are highly aggressive, metastatic, and chemo-resistant (11-16,21,39).  Importantly, 
several of these studies have shown that knocking-down tTG expression in cancer cells with 
siRNAs, or treating cells with competitive inhibitors that bind at the transamidation active site of 
tTG, often sensitizes these cancer cells to chemotherapeutic agents and reduces many of their 
transformed features (11-16).  While these findings point to tTG as being an important player in 
cancer progression, exactly how tTG contributes to the malignant state and whether it represents 
a valid target for cancer therapy, remains to be determined. 
 In this study, our goal was to use a simplified model system to better understand the 
intrinsic capability of tTG to confer cellular changes that might shed important light on the role 
that it plays in cancer progression.  Thus, we sought to examine the actions of tTG in a non- 
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 Figure 3.7  Model depicting how tTG brings Src and PI3-kinase together to enhance 
signaling and promote cell survival.  Our results suggest that tTG functions as a scaffold 
and brings Src and PI3-kinase into close proximity to one another.  Src is then able to 
phosphorylate the p85 regulatory subunit of PI3-kinase causing it to adopt a conformation that 
allows the p110 catalytic subunit of PI3-kinase to become activated and signal to its 
downstream effectors.  The tTG-mediated activation of the PI3-kinase pathway promotes cell 
survival.   
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transformed cellular context, specifically NIH3T3 fibroblasts, so as to avoid the aberrant 
oncogenic signaling inputs characteristic of transformed/cancer cells that might complicate the 
picture.  In fact, we found that the stable over-expression of tTG in NIH3T3 fibroblasts did not 
cause the cells to lose their normal contact inhibition and form foci when grown in monolayer,  
nor did it enhance their migration.  However, interestingly, we discovered that tTG provided a 
marked survival advantage to the cells, when challenged with serum starvation.  This finding was 
consistent with our earlier observations that tTG confers cancer cells with a strong protective 
effect against apoptotic stresses, such as those elicited by treatment of cells with 
chemotherapeutic agents, and thus potentially would explain the advantage provided by the over-
expression of tTG in high grade and highly aggressive forms of human cancer (6,39) 
 So how does the over-expression of tTG in non-transformed fibroblasts enhance their 
survival capability?  We obtained an interesting clue when we analyzed the activities of 
components of the MAP kinase and PI3-kinase signaling pathways and found that significant 
increases in the activation of AKT, mTOR, and p70 S6-kinase occurred in the tTG-expressing 
fibroblasts, compared to those expressing the vector alone.  These results led us to suspect that 
tTG promotes cell survival by enhancing the activation of the PI3-kinase/mTOR/p70 S6-kinase 
pathway. 
 This raised an important question, namely, how is tTG able to activate the PI3-kinase 
pathway?  While there had been suggestions in the literature that tTG may regulate the levels of 
PTEN, and in turn, enhance AKT activation (22), we assessed the levels of PTEN in the NIH3T3 
stable cell lines and found that they were unaffected by tTG.  This led us to examine whether c-
Src is contributing to the activation of PI3-kinase in tTG-expressing fibroblasts.  c-Src binds PI3-
kinase and requires this interaction to promote cellular transformation (31-33,36,37).  Given our 
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recent findings in the human breast cancer cell line SKBR3, that tTG is able to bind and increase 
c-Src activity in response to EGF treatment (20), we wondered whether a similar mechanism 
might be operating in fibroblasts over-expressing tTG.  Indeed, we found that the activation of 
the PI3-kinase pathway to mTOR, and p70 S6-kinase in NIH3T3 cells over-expressing tTG is 
sensitive to Src inhibition.   
 Since we had shown previously that Src co-immunoprecipitates with tTG, and it has been 
reported that Src can bind to and activate PI3-kinase, we examined the possibility that Src, tTG, 
and PI3-kinase formed a ‘signaling complex’.  Indeed, we discovered that in addition to binding 
Src, tTG can be co-immunoprecipitated with both the p110 catalytic subunit and the p85 
regulatory subunit of PI3-kinase.  We reasoned that if the assembly of a complex that includes 
tTG, Src, and PI3-kinase is essential for sending a survival signal, then we would expect that 
inhibitors like MDC and PP2 which block these signals would have a corresponding inhibitory 
effect on complex formation.  Interestingly, while inhibiting tTG and Src activity had no effect 
on the ability of tTG to be co-immunoprecipitated with p85, we found that disabling these 
signaling proteins completely blocked the interaction between tTG and Src.  These results 
suggest that the tTG-p85 interaction is not dependent on having access to the transamidation 
active site of tTG, which would be blocked by MDC, whereas, the ability of Src to bind tTG 
requires such access.  This observation correlates with our previous finding in breast cancer cells 
that Src is unable to bind a transamidation-defective form of tTG generated by mutation of the 
active site cysteine, C277V (20).  These results imply that Src and p85 have different 
requirements for binding to tTG and do so in separate regions of tTG.  Importantly, however, 
disrupting the ability of tTG to associate with Src eliminates the Src-mediated tyrosine 
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phosphorylation of p85, which in turn reduces the activation of the PI3-kinase signaling 
pathway. 
 Collectively, these findings point to a novel mechanism by which tTG is capable of 
triggering signals essential for cell survival (Figure 3.7).  Given the established link between Src 
and PI3-kinase, it is clear that these two proteins can work together to promote cellular 
transformation, particularly in cells expressing oncogenic Src mutants.  However, we now find 
that tTG, when over-expressed even in a non-transformed cellular setting, is capable of 
facilitating the assembly of a complex that includes c-Src and PI3-kinase, apparently bringing 
them into close proximity so as to allow Src to directly phosphorylate PI3-kinase, resulting in its 
activation and an ensuing stimulation of cell survival.  These findings also offer important 
insights into how the over-expression of tTG in cancer cells can have important consequences 
that enable their survival in the face of stress and apoptotic signals such as chemotherapeutic 
drugs, and thus highlight tTG as a potentially an important therapeutic target in human cancer.   
 
Materials and Methods 
Materials.  All cell culture reagents (unless mentioned otherwise), Lipofectamine, and protein G 
agarose beads were from Invitrogen.  Monodansylcadaverine (MDC) and 6-diamidino-2-
phenylindole (DAPI) were obtained from Sigma, while PP2, LY294002, and rapamycin were 
from Calbiochem.  Biotinylated pentylamine (BPA) was obtained from Pierce, and the Myc and 
HA antibodies were from Covance.  The Ras and pan-p70 S6-kinase antibodies were from 
Millipore, the tTG antibody was from Zedira, and the actin antibody was from Neomarkers.  The 
anti-phosphotyrosine antibody, as well as the antibodies that recognize the total, activated, and/or 
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phosphorylated forms of ERK, c-Jun, AKT, mTOR, p70 S6-kinase, and PTEN were from Cell 
Signaling. 
 
Cell Culture.  Parental NIH3T3 cells were grown in DMEM containing 10% calf serum (CS), 
while HEK293T cells were grown in DMEM containing 10% fetal bovine serum (FBS).  The 
pcDNA3 constructs encoding the Myc-tagged form of tTG and the HA-tagged forms of H-Ras 
G12V, c-Src, v-Src, p85, or p110, were transfected into cells using Lipofectamine.  Clones of 
NIH3T3 mouse fibroblasts stably expressing the vector alone or a Myc-tagged form of wild-type 
tTG were selected by culturing the cells in DMEM containing 10% CS and 2 μg/mL puromycin.  
Once individual clones expressing either the vector alone or the Myc-tagged form of tTG were 
obtained, the cells were then maintained in the same growth medium supplemented with 0.5 
μg/mL puromycin.  Where indicated, cells were treated with 50 μM MDC, 10 μM PP2, 10 μM 
LY294002, or 50 nM rapamycin.  Cells were lysed with cell lysis buffer (25 mM Tris, 100 mM 
NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO4, 1 mM β-glycerol phosphate, 
1 μg/mL aprotinin, 1 μg/mL leupeptin).  The Bio-Rad DC protein assay was used to determine 
the protein concentrations of the cell lysates.  
 
Transamidation Activity Assays.  Fifteen micrograms of whole cell extracts collected from 
parental NIH3T3 cells or NIH3T3 cells stably expressing the vector alone or a Myc-tagged form 
of tTG, were incubated in a buffer containing 10 mM dithiothreitol, 10 mM CaCl2, and 50 μM 
BPA for 10 minutes followed by the addition of Laemmli sample buffer.  The samples were 
boiled, subjected to SDS-PAGE, transferred to polyvinylidene fluoride (PVDF) membranes, and 
blocked for one day in BBST (100 mM boric acid, 20 mM sodium borate, 0.01% SDS, 0.01% 
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Tween 20, 80 mM NaCl) containing 10% bovine serum albumin (BSA).  The PVDF membranes 
were then incubated with horseradish-peroxidase-conjugated streptavidin at a dilution of 1:2000 
in BBST containing 5% BSA for one hour, followed by extensive washing with BBST.  The 
membranes were then exposed to ECL reagent and the proteins that had incorporated BPA were 
visualized using x-ray film. 
 
Focus Formation Assays.  Nearly confluent cultures of fibroblasts were transfected without 
(Mock) or with expression plasmids encoding a Myc-tagged form of tTG or an HA-tagged form 
of activated H-Ras (H-Ras G12V) and were maintained in DMEM containing 10% CS for 10 
days.  The cells were then fixed with 3.7% formaldehyde and stained with 0.4% crystal violet to 
visualize any resulting foci that formed. 
 
Cell Migration (Scratch) Assays.  Multiple sets of NIH3T3 cells stably expressing either the 
vector alone or a Myc-tagged form of tTG were grown to confluence, at which time a wound was 
struck down the center of each plate using a pipet tip and the cultures rinsed with phosphate 
buffered saline to remove the detached cells.  One set of cells was immediately fixed with 3.7% 
formaldehyde after striking the wound to indicate the size of the initial wound.  The remaining 
sets of cells were then placed in DMEM containing 0.1% CS for one day before being fixed.  
The ability of the cells to migrate into the wound was visualized by light microscopy and 
photographed. 
 
Cell Growth Assays.  Multiple sets of NIH3T3 cells stably expressing the vector alone or a Myc-
tagged form of tTG were plated in 6-well dishes at a density of 2 x 10
4
 cells/dish and maintained 
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in DMEM containing 0.1% CS.  One set of the cells was counted every two days, while the 
medium on the remaining sets of cells was replenished.  The growth assays were carried-out over 
a span of 6 days.  
 
Apoptotic Assays.  NIH3T3 cells stably expressing either the vector alone or a Myc-tagged form 
of tTG were seeded in 6-well dishes and then maintained in serum-free medium without or with 
PP2, LY294002, or rapamycin for 36 hours.  The cells (both floating and attached) were then 
collected and stained with DAPI (2 μg/mL) for viewing by fluorescence microscopy.  Apoptotic 
cells were identified by condensed and/or blebbed nuclei.  
 
Immunoprecipitations.  Cell lysates (typically 1.2 mg) were initially pre-cleared using protein G 
agarose beads.  The pre-cleared lysates were then incubated with HA antibody for 1.5 hours, 
followed by the addition of protein G agarose beads for another 1.5 hours.  After extensive 
washing of the beads with cell lysis buffer, Laemmli sample buffer was added to the beads and 
the samples were boiled.  
 
Immunoblot Analysis.  Whole cell lysates or the resulting immunoprecipitations that were 
performed were resolved by SDS-PAGE and the proteins were transferred to PVDF membranes.  
The membranes were incubated in primary antibodies prepared in 20 mM Tris, 135 mM NaCl, 
and 0.02% Tween 20.  Horseradish-peroxidase conjugated secondary antibodies were used to 
detect the primary antibodies, followed by exposure to ECL reagent. 
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CHAPTER 4 
 
Conclusions 
 
The localization of tTG at leading edges is important for cancer cell migration 
 The second chapter of this thesis described our findings regarding the importance of 
localizing tTG to leading edges for cancer cell migration.  In this study, we determined that a 
small fraction of tTG (~10%) is constitutively associated with the plasma membrane and is 
activated and recruited to the leading edges of HeLa cervical carcinoma cells upon EGF 
stimulation.  Given that tTG has no obvious membrane-interaction motif in its sequence, we 
hypothesized that a protein may be binding to tTG to facilitate its re-distribution along the 
leading edges in response to EGF.  Immunoprecipitations of tTG from the membrane fractions of 
HeLa cells treated with EGF, led to the discovery that tTG binds the heat shock protein (Hsp)70 
family of molecular chaperones.  Both tTG and Hsp70 co-localize to leading edges and this 
localization is dependent on the chaperonin activity of Hsp70, as inhibitors against this function, 
prevent Hsp70 and tTG from localizing to leading edges.  Importantly, these inhibitors also block 
the EGF-dependent migration of HeLa cells and the constitutive migration of MDA-MB231 
cells, suggesting that the ability of tTG and Hsp70 to localize to leading edges is critical for cell 
motility. 
 These findings raise important questions regarding the nature of the relationship between 
tTG and Hsp70.  Is tTG a client of Hsp70?  Heat shock chaperones have specific client proteins 
and the expression, folding, or activation of these clients may be regulated by their respective 
chaperone (1,2).  Inhibitors which block the function of heat shock proteins often lead to 
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decreased expression of these clients, thus many researchers have used this outcome as an 
indicator of chaperone-client interactions.  In our experiments, no decrease in tTG expression 
was observed upon inhibition of Hsp70, suggesting that tTG is not a conventional client of 
Hsp70.  However, given that these inhibitors do have an effect on the localization of Hsp70 and 
tTG to leading edges, this would suggest that an unknown client protein is involved in this 
regulation of tTG’s sub-cellular localization.  One attractive candidate for this client protein is c-
Jun N-terminal kinase (JNK), given that Ras signaling through JNK was shown to regulate tTG 
activity and localization to leading edges.  If Hsp70 were capable of regulating JNK expression 
and/or activation, this could help explain how Hsp70 promotes tTG localization to leading edges.  
While there is currently no evidence to support this hypothesis, the identification of this client is 
an important aspect for shedding light on the regulation of tTG. 
 These studies have also illustrated a novel role for heat shock proteins, namely to regulate 
the sub-cellular localization of a protein (tTG) to promote its role in cell migration.  Heat shock 
proteins are generally classified as molecular chaperones, helping denatured proteins re-fold, or 
in some cases, helping to target these proteins for degradation by the proteosome when they are 
unable to be re-folded (1,2).  However, in recent years researchers have discovered that these 
chaperones may help activate certain clients, in particular various signaling proteins such as Src 
kinase or B-Raf, and allow them to persist in an activated state even when they should be 
inactivated or degraded (2,3).  As a result, there is much interest in heat shock proteins as a 
potential therapeutic target for the treatment of human cancer where aberrant cell signaling often 
contributes to malignant transformation (1,4,5).  The finding that Hsp70 regulates the 
localization of tTG to leading edges, suggests that heat shock proteins may influence 
oncogenesis by helping proteins localize properly in order to carry-out their functions. 
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 While we know that the ability of Hsp70 and tTG to localize to leading edges is 
important for the EGF-dependent migration of HeLa cells and the constitutive migration of 
MDA-MB231 cells, what tTG does at the leading edge to enhance motility is still unclear.  Our 
initial hypothesis was that tTG may encounter a certain substrate at the leading edge and cross-
link it to promote cell migration.  One such substrate could be actin, as tTG has been shown to 
bind and cross-link actin in vitro (6).  However, future studies will be necessary to determine the 
substrate(s) of tTG that may reside at the leading edge and whether cross-linking of this 
substrate(s) is important for tTG’s ability to drive cell migration.  To do this, one could isolate 
the membrane fractions of HeLa cells stimulated with EGF and perform tTG transamidation 
activity assays whereby the lysates will be incubated with calcium and a biotin-labeled substrate, 
i.e. biotinylated pentylamine (BPA).  The crosslinked proteins can be purified using an affinity 
column with a resin of monomeric avidin and identified by mass spectrometry. Following 
identification of potential tTG substrates, the next step would involve knocking-down these 
proteins to determine if cell migration is impacted.  Should these experiments lead to the 
discovery of a physiologically relevant tTG substrate important for cell migration, one could go 
on to generate a mutant form of this protein that cannot be crosslinked by tTG and determine 
whether crosslinking is critical for the ability of this substrate to promote cell migration. 
 However, in light of our second study (Chapter 3), the alternative possibility is that tTG 
regulates signaling events which may impact cell migration.  Indeed, signaling proteins such as 
the EGF receptor and PI3-kinase have been shown to localize to leading edges (7).  In this way, 
the leading edge may not simply be a structure for physically directing migration, but could also 
serve as a signaling hub where various proteins interact, leading to the activation of signaling 
networks which facilitate cell movement. 
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tTG plays a fundamental role in promoting cell survival 
 While there had been many studies describing the importance of tTG in cancer 
progression, to what degree tTG cooperated with oncogenic proteins in these cancer cell 
contexts, versus its intrinsic ability to promote malignant transformation was unknown.  With 
this in mind, we set out to determine how the ectopic expression of tTG in a normal (non-
transformed) cellular background would influence the behavior of the cells.  Using NIH3T3 
fibroblasts stably expressing the vector alone or a Myc-tagged form of tTG, we found that tTG 
strongly protected these cells from serum-starvation-induced apoptosis by activating the PI3-
kinase/mTOR/p70 S6-kinase pathway.  Moreover, tTG formed a ‘signaling complex’ with the 
non-receptor tyrosine kinase c-Src and PI3-kinase, which was important for the activation of the 
PI3-kinase pathway leading to enhanced cell survival. 
 While the evidence suggests that tTG has an inherent role in promoting cell survival, 
much remains to be learned about the interactions between tTG, c-Src, and PI3-kinase and how 
the formation of this signaling complex really leads to the enhanced signaling and survival 
observed in the fibroblast system.  Some of the more obvious lines of study could involve 
determining which region of tTG binds to c-Src and PI3-kinase and testing to see whether 
mutations can disrupt these interactions.  The best scenario would be to generate a tTG mutant 
incapable of binding either Src or PI3-kinase, and test this mutant to see whether the enhanced 
signaling and survival advantage is lost.  This would provide more detail as to how this complex 
forms and confirm the importance of this complex in the signaling and survival outcomes. 
 In addition, this mechanism needs to be evaluated in the context of human cancer cells.  
Of particular interest would be those cancer cells known to have elevated activation of Src or 
PI3-kinase, without direct mutation of either of these signaling proteins.  Preliminary studies 
141
using the lung carcinoma cell line, A549, have supported our findings in fibroblasts.  These cells 
express high levels of TG and show activation of the PI3-kinase/mTOR/p70 S6-kinase pathway.  
Treatment of the cells with inhibitors against tTG function (MDC) or Src activity (PP2), blocks 
the activation of this pathway and significantly inhibits transformation as read-out by reduced 
colony formation in soft agar assays.  Determining which cancer types or cell lines utilize this 
mechanism will be important for understanding how tTG can globally impact cancer 
progression.  
The role of tTG in Ras-driven cellular transformation 
 Given that our studies have shown that tTG inherently functions to promote cell survival 
through a Src-PI3-kinase dependent pathway, an important question concerns how tTG 
cooperates with oncogenes, such as Ras to drive oncogenesis.  Ras is one of the most commonly 
mutated genes in human cancer, with a mutation frequency of ~30% in all types of cancer (8,9).  
Our early studies on the role of tTG in EGF-dependent migration showed that the EGF receptor 
signaled through Ras to direct changes in tTG activity and localization, suggesting that Ras and 
tTG may work together to promote cancer cell migration.  This was determined using HeLa cells 
stably expressing the vector alone or an activated form of H-Ras (H-Ras G12V), whereby tTG 
was constitutively activated and localized to leading edges in the activated Ras-expressing cells 
compared to those expressing the vector alone.  At this same time, we decided to analyze the role 
of tTG in Ras-driven transformation by performing soft agar assays without or with a tTG 
inhibitor (MDC).  As expected, the cells stably expressing activated Ras formed larger and more 
numerous colonies compared to the vector-alone expressing cells.  However, MDC treatment of 
the Ras-expressing cells led to a significant reduction in colony formation, suggesting that tTG 
was important for the transforming potential of Ras. 
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Figure 4.1  tTG synergizes with activated Ras to form foci.  Cultures of NIH3T3 cells 
stably expressing the vector alone or a Myc-tagged form of wild-type tTG were transfected 
without (Mock) or with HA-tagged forms of wild-type (H-Ras WT) or activated Ras (H-Ras 
G12V).  One set of cultures was lysed and subjected to Western blot analysis using the 
indicated antibodies.  The other cultures were maintained in DMEM supplemented with 10% 
calf serum and 0.5 μg/mL puromycin for 10 days.  The cells were then fixed with 3.7% 
formaldehyde and stained with 0.4% crystal violet to indicate differences in foci.  
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With this in mind, we decided to read-out the impact of tTG on Ras-driven focus 
formation in another model system, the NIH3T3 fibroblasts stably expressing the vector alone or 
a Myc-tagged form of tTG.  Expression of an activated form of H-Ras (H-Ras G12V) has been 
shown to induce transformation in several fibroblast cell lines by allowing the cells to overcome 
cell contact inhibition and form foci (i.e. areas of high cell density) (10).  Interestingly, when Ras 
was ectopically expressed in the NIH3T3 fibroblasts stably expressing the vector alone or Myc-
tagged tTG, we observed that expression of Ras in the tTG-expressing fibroblasts led to a much 
greater number of foci compared to expression of Ras in the vector-alone expressing fibroblasts 
(Figure 4.1).  Thus, in this model system, Ras and tTG were able to synergize and enhance 
transformation.  
 We next examined the importance of tTG in human cancer cells known to possess 
mutations in K-Ras, including A549 lung carcinoma cells, MiA PaCa-2 and PANC-1 pancreatic 
cancer cells.  Figure 4.2A shows that in these cell lines, tTG is highly expressed and activated.  
More importantly, tTG is required for the transforming ability of these cells as inhibiting its 
transamidation activity using MDC or knocking-down tTG using siRNAs significantly blocks 
the ability of the cells to form colonies in soft agar (Figures 4.2B and 4.2C, respectively).  These 
findings suggest that tTG may play an important role in promoting Ras-driven transformation.  
We are currently investigating the role of tTG in these cell lines, specifically to see whether tTG 
works with Src and PI3-kinase to synergize with Ras and influence cellular transformation, as 
highlighted in Figure 4.3. 
 Overall these findings point to tTG playing a critical role in cellular transformation, 
influencing both cell survival and motility.  They also suggest that tTG may be an important 
candidate for the development of therapies to target cancer cells.  Future studies into the efficacy  
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 Figure 4.2  K-Ras transformation is dependent on tTG.  (A) A549, MIA PaCa-2, and 
PANC-1 cells were maintained in serum-free medium for 24 hours, lysed, and subjected to 
Western blot analysis.  The same lysates were also assayed for tTG transamidation activity by 
determining the incorporation of biotinylated pentylamine (BPA) into lysate proteins.  (B)  
Anchorage independent growth assays were performed on A549, MIA PaCa-2, and PANC-1 
cells treated without or with MDC.  Three separate assays were performed and the results 
were averaged.  The error bars indicate the standard deviation.  (C) Cultures of A549, MIA 
PaCa-2, and PANC-1 cells were transfected with control or two different tTG siRNAs.  One 
set of cultures was subjected to Western blot analysis (left panels), while the remaining 
lysates were used to perform anchorage independent growth assays (right panel).  Three 
separate assays were performed and the results were averaged.  The error bars indicate the 
standard deviation. 
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of targeting tTG will be very valuable.  Though there is the possibility that tTG may play some 
undiscovered role in normal development and may not be the best candidate for therapeutic 
intervention, there is a growing amount of evidence which contradicts this idea and favors the 
hypothesis that tTG is a worthwhile target.  
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 Figure 4.3  tTG may influence Ras transformation by activating Src and PI3-kinase.  
Based on our previous findings that tTG can bind Src and PI3-kinase in NIH3T3 mouse 
fibroblasts and induce the activation of the PI3-kinase signaling to promote cell survival, it 
will be important to determine if the same mechanism applies in the context of Ras-driven 
cancer cells.  
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